{
  "DOI": "10.1186/s40246-021-00329-0",
  "ISSN": [
    "1479-7364"
  ],
  "URL": "http://dx.doi.org/10.1186/s40246-021-00329-0",
  "abstract": "\u003cjats:title\u003eAbstract\u003c/jats:title\u003e\u003cjats:p\u003eFor decades, various strategies have been proposed to solve the enigma of hemoglobinopathies, especially severe cases. However, most of them seem to be lagging in terms of effectiveness and safety. So far, the most prevalent and promising treatment options for patients with β-types hemoglobinopathies, among others, predominantly include drug treatment and gene therapy. Despite the significant improvements of such interventions to the patient’s quality of life, a variable response has been demonstrated among different groups of patients and populations. This is essentially due to the complexity of the disease and other genetic factors. In recent years, a more in-depth understanding of the molecular basis of the β-type hemoglobinopathies has led to significant upgrades to the current technologies, as well as the addition of new ones attempting to elucidate these barriers. Therefore, the purpose of this article is to shed light on pharmacogenomics, gene addition, and genome editing technologies, and consequently, their potential use as direct and indirect genome-based interventions, in different strategies, referring to drug and gene therapy. Furthermore, all the latest progress, updates, and scientific achievements for patients with β-type hemoglobinopathies will be described in detail.\u003c/jats:p\u003e",
  "alternative-id": [
    "329"
  ],
  "article-number": "32",
  "assertion": [
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Received",
      "name": "received",
      "order": 1,
      "value": "6 February 2021"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Accepted",
      "name": "accepted",
      "order": 2,
      "value": "28 April 2021"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "First Online",
      "name": "first_online",
      "order": 3,
      "value": "5 June 2021"
    },
    {
      "group": {
        "label": "Declarations",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 1
    },
    {
      "group": {
        "label": "Ethics approval and consent to participate",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 2,
      "value": "Not applicable."
    },
    {
      "group": {
        "label": "Consent for publication",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 3,
      "value": "Not applicable."
    },
    {
      "group": {
        "label": "Competing interests",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 4,
      "value": "GPP is a Full Member and National Representative at the European Medicines Agency, Committee for Human medicinal Products (CHMP)–Pharmacogenomics Working Party, Amsterdam, the Netherlands."
    }
  ],
  "author": [
    {
      "ORCID": "http://orcid.org/0000-0002-3085-7799",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Karamperis",
      "given": "Kariofyllis",
      "sequence": "first"
    },
    {
      "affiliation": [],
      "family": "Tsoumpeli",
      "given": "Maria T.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Kounelis",
      "given": "Fotios",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Koromina",
      "given": "Maria",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Mitropoulou",
      "given": "Christina",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Moutinho",
      "given": "Catia",
      "sequence": "additional"
    },
    {
      "ORCID": "http://orcid.org/0000-0002-0519-7776",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Patrinos",
      "given": "George P.",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "Human Genomics"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": [
      "link.springer.com"
    ]
  },
  "created": {
    "date-parts": [
      [
        2021,
        6,
        5
      ]
    ],
    "date-time": "2021-06-05T10:02:54Z",
    "timestamp": 1622887374000
  },
  "deposited": {
    "date-parts": [
      [
        2023,
        2,
        3
      ]
    ],
    "date-time": "2023-02-03T15:17:45Z",
    "timestamp": 1675437465000
  },
  "indexed": {
    "date-parts": [
      [
        2024,
        4,
        12
      ]
    ],
    "date-time": "2024-04-12T08:24:17Z",
    "timestamp": 1712910257410
  },
  "is-referenced-by-count": 10,
  "issn-type": [
    {
      "type": "electronic",
      "value": "1479-7364"
    }
  ],
  "issue": "1",
  "issued": {
    "date-parts": [
      [
        2021,
        6,
        5
      ]
    ]
  },
  "journal-issue": {
    "issue": "1",
    "published-online": {
      "date-parts": [
        [
          2021,
          12
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2021,
            6,
            5
          ]
        ],
        "date-time": "2021-06-05T00:00:00Z",
        "timestamp": 1622851200000
      }
    },
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "vor",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2021,
            6,
            5
          ]
        ],
        "date-time": "2021-06-05T00:00:00Z",
        "timestamp": 1622851200000
      }
    }
  ],
  "link": [
    {
      "URL": "https://link.springer.com/content/pdf/10.1186/s40246-021-00329-0.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/article/10.1186/s40246-021-00329-0/fulltext.html",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/content/pdf/10.1186/s40246-021-00329-0.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "prefix": "10.1186",
  "published": {
    "date-parts": [
      [
        2021,
        6,
        5
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2021,
        6,
        5
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "DOI": "10.1016/S0140-6736(17)31822-6",
      "author": "AT Taher",
      "doi-asserted-by": "publisher",
      "first-page": "155",
      "issue": "10116",
      "journal-title": "Lancet",
      "key": "329_CR1",
      "unstructured": "Taher AT, Weatherall DJ, Cappellini MD. Thalassaemia. Lancet. 2018;391(10116):155–67.",
      "volume": "391",
      "year": "2018"
    },
    {
      "DOI": "10.2174/156652408786241375",
      "author": "DJ Weatherall",
      "doi-asserted-by": "publisher",
      "first-page": "592",
      "issue": "7",
      "journal-title": "Curr Mol Med.",
      "key": "329_CR2",
      "unstructured": "Weatherall DJ. Hemoglobinopathies worldwide: present and future. Curr Mol Med. 2008;8(7):592–9.",
      "volume": "8",
      "year": "2008"
    },
    {
      "DOI": "10.1111/bjh.15038",
      "author": "DS Vinjamur",
      "doi-asserted-by": "publisher",
      "first-page": "630",
      "journal-title": "Br J Haematol",
      "key": "329_CR3",
      "unstructured": "Vinjamur DS, Bauer DE, Orkin SH. Recent progress in understanding and manipulating haemoglobin switching for the haemoglobinopathies. Br J Haematol. 2018;180:630–43.",
      "volume": "180",
      "year": "2018"
    },
    {
      "DOI": "10.1182/asheducation-2013.1.354",
      "author": "SL Thein",
      "doi-asserted-by": "publisher",
      "first-page": "354",
      "journal-title": "Hematol Am Soc Hematol Educ Program.",
      "key": "329_CR4",
      "unstructured": "Thein SL. Genetic association studies in β-hemoglobinopathies. Hematol Am Soc Hematol Educ Program. 2013;2013:354–61.",
      "volume": "2013",
      "year": "2013"
    },
    {
      "DOI": "10.1016/j.hoc.2017.11.008",
      "author": "DJ Weatherall",
      "doi-asserted-by": "publisher",
      "first-page": "165",
      "issue": "2",
      "journal-title": "Hematol Oncol Clin North Am.",
      "key": "329_CR5",
      "unstructured": "Weatherall DJ. The evolving spectrum of the epidemiology of thalassemia. Hematol Oncol Clin North Am. 2018;32(2):165–75.",
      "volume": "32",
      "year": "2018"
    },
    {
      "DOI": "10.1007/s40265-020-01341-9",
      "author": "I Motta",
      "doi-asserted-by": "publisher",
      "first-page": "1053",
      "issue": "11",
      "journal-title": "Drugs.",
      "key": "329_CR6",
      "unstructured": "Motta I, Bou-Fakhredin R, Taher AT, Cappellini MD. Beta thalassemia: new therapeutic options beyond transfusion and iron chelation. Drugs. 2020;80(11):1053–63.",
      "volume": "80",
      "year": "2020"
    },
    {
      "DOI": "10.1016/S0140-6736(11)60283-3",
      "author": "DR Higgs",
      "doi-asserted-by": "publisher",
      "first-page": "373",
      "issue": "9813",
      "journal-title": "Lancet",
      "key": "329_CR7",
      "unstructured": "Higgs DR, Engel JD, Stamatoyannopoulos G. Thalassaemia. Lancet. 2012;379(9813):373–83.",
      "volume": "379",
      "year": "2012"
    },
    {
      "DOI": "10.1038/nm.3814",
      "author": "VG Sankaran",
      "doi-asserted-by": "publisher",
      "first-page": "221",
      "issue": "3",
      "journal-title": "Nat Med.",
      "key": "329_CR8",
      "unstructured": "Sankaran VG, Weiss MJ. Anemia: progress in molecular mechanisms and therapies. Nat Med. 2015;21(3):221–30.",
      "volume": "21",
      "year": "2015"
    },
    {
      "DOI": "10.2471/BLT.06.036673",
      "author": "B Modell",
      "doi-asserted-by": "publisher",
      "first-page": "480",
      "issue": "6",
      "journal-title": "Bull World Health Organ.",
      "key": "329_CR9",
      "unstructured": "Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008;86(6):480–7.",
      "volume": "86",
      "year": "2008"
    },
    {
      "DOI": "10.1155/2013/727905",
      "author": "M Angastiniotis",
      "doi-asserted-by": "publisher",
      "first-page": "727905",
      "journal-title": "ScientificWorldJ.",
      "key": "329_CR10",
      "unstructured": "Angastiniotis M, Vives Corrons JL, Soteriades ES, Eleftheriou A. The impact of migrations on the health services for rare diseases in Europe: the example of haemoglobin disorders. ScientificWorldJ. 2013;2013:727905.",
      "volume": "2013",
      "year": "2013"
    },
    {
      "DOI": "10.1136/archdischild-2014-308112",
      "author": "A Amid",
      "doi-asserted-by": "publisher",
      "first-page": "1051",
      "issue": "11",
      "journal-title": "Arch Dis Child.",
      "key": "329_CR11",
      "unstructured": "Amid A, Saliba AN, Taher AT, Klaassen RJ. Thalassaemia in children: from quality of care to quality of life. Arch Dis Child. 2015;100(11):1051–7.",
      "volume": "100",
      "year": "2015"
    },
    {
      "DOI": "10.4084/mjhid.2017.018",
      "author": "V De Sanctis",
      "doi-asserted-by": "publisher",
      "first-page": "e2017018",
      "issue": "1",
      "journal-title": "Mediterr J Hematol Infect Dis",
      "key": "329_CR12",
      "unstructured": "De Sanctis V, Kattamis C, Canatan D, Soliman AT, Elsedfy H, Karimi M, et al. β-thalassemia distribution in the old world: an ancient disease seen from a historical standpoint. Mediterr J Hematol Infect Dis. 2017;9(1):e2017018.",
      "volume": "9",
      "year": "2017"
    },
    {
      "DOI": "10.1182/blood-2010-01-251348",
      "author": "DJ Weatherall",
      "doi-asserted-by": "publisher",
      "first-page": "4331",
      "issue": "22",
      "journal-title": "Blood",
      "key": "329_CR13",
      "unstructured": "Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood. 2010;115(22):4331–6.",
      "volume": "115",
      "year": "2010"
    },
    {
      "author": "E Kohne",
      "first-page": "532",
      "issue": "31-32",
      "journal-title": "Dtsch Arztebl Int.",
      "key": "329_CR14",
      "unstructured": "Kohne E. Hemoglobinopathies: clinical manifestations, diagnosis, and treatment. Dtsch Arztebl Int. 2011;108(31-32):532–40.",
      "volume": "108",
      "year": "2011"
    },
    {
      "author": "AD Fard",
      "first-page": "47",
      "issue": "3",
      "journal-title": "Int J Hematol Oncol Stem Cell Res.",
      "key": "329_CR15",
      "unstructured": "Fard AD, Hosseini SA, Shahjahani M, Salari F, Jaseb K. Evaluation of novel fetal hemoglobin inducer drugs in treatment of β-hemoglobinopathy disorders. Int J Hematol Oncol Stem Cell Res. 2013;7(3):47–54.",
      "volume": "7",
      "year": "2013"
    },
    {
      "DOI": "10.1101/cshperspect.a011684",
      "author": "BG Forget",
      "doi-asserted-by": "publisher",
      "first-page": "a011684",
      "issue": "2",
      "journal-title": "Cold Spring Harb Perspect Med",
      "key": "329_CR16",
      "unstructured": "Forget BG, Bunn HF. Classification of the disorders of hemoglobin. Cold Spring Harb Perspect Med. 2013;3(2):a011684.",
      "volume": "3",
      "year": "2013"
    },
    {
      "DOI": "10.4084/MJHID.2019.002",
      "author": "A Matte",
      "doi-asserted-by": "publisher",
      "first-page": "e2019002",
      "issue": "1",
      "journal-title": "Mediterr J Hematol Infect Dis",
      "key": "329_CR17",
      "unstructured": "Matte A, Zorzi F, Mazzi F, Federti E, Olivieri O, De Franceschi L. New therapeutic options for the treatment of sickle cell disease. Mediterr J Hematol Infect Dis. 2019;11(1):e2019002. https://doi.org/10.4084/MJHID.2019.002.",
      "volume": "11",
      "year": "2019"
    },
    {
      "DOI": "10.1016/j.bcmd.2017.06.001",
      "author": "SL Thein",
      "doi-asserted-by": "publisher",
      "first-page": "54",
      "journal-title": "Blood Cells Mol Dis.",
      "key": "329_CR18",
      "unstructured": "Thein SL. Molecular basis of β thalassemia and potential therapeutic targets. Blood Cells Mol Dis. 2018;70:54–65.",
      "volume": "70",
      "year": "2018"
    },
    {
      "DOI": "10.1016/j.blre.2019.100588",
      "author": "FT Shah",
      "doi-asserted-by": "publisher",
      "first-page": "100588",
      "journal-title": "Blood Rev.",
      "key": "329_CR19",
      "unstructured": "Shah FT, Sayani F, Trompeter S, Drasar E, Piga A. Challenges of blood transfusions in β-thalassemia. Blood Rev. 2019;37:100588.",
      "volume": "37",
      "year": "2019"
    },
    {
      "DOI": "10.1097/MOH.0000000000000286",
      "author": "S Issaragrisil",
      "doi-asserted-by": "publisher",
      "first-page": "508",
      "issue": "6",
      "journal-title": "Curr Opin Hematol.",
      "key": "329_CR20",
      "unstructured": "Issaragrisil S, Kunacheewa C. Matched sibling donor hematopoietic stem cell transplantation for thalassemia. Curr Opin Hematol. 2016;23(6):508–14.",
      "volume": "23",
      "year": "2016"
    },
    {
      "DOI": "10.1097/00008480-200302000-00005",
      "author": "J Gaziev",
      "doi-asserted-by": "publisher",
      "first-page": "24",
      "issue": "1",
      "journal-title": "Curr Opin Pediatr.",
      "key": "329_CR21",
      "unstructured": "Gaziev J, Lucarelli G. Stem cell transplantation for hemoglobinopathies. Curr Opin Pediatr. 2003;15(1):24–31.",
      "volume": "15",
      "year": "2003"
    },
    {
      "DOI": "10.1016/j.bj.2015.10.001",
      "author": "E de Dreuzy",
      "doi-asserted-by": "publisher",
      "first-page": "24",
      "issue": "1",
      "journal-title": "Biomed J.",
      "key": "329_CR22",
      "unstructured": "de Dreuzy E, Bhukhai K, Leboulch P, Payen E. Current and future alternative therapies for beta-thalassemia major. Biomed J. 2016;39(1):24–38.",
      "volume": "39",
      "year": "2016"
    },
    {
      "DOI": "10.4084/mjhid.2019.067",
      "author": "I Motta",
      "doi-asserted-by": "publisher",
      "first-page": "e2019067",
      "issue": "1",
      "journal-title": "Mediterr J Hematol Infect Dis.",
      "key": "329_CR23",
      "unstructured": "Motta I, Ghiaccio V, Cosentino A, Breda L. Curing hemoglobinopathies: challenges and advances of conventional and new gene therapy approaches. Mediterr J Hematol Infect Dis. 2019;11(1):e2019067.",
      "volume": "11",
      "year": "2019"
    },
    {
      "DOI": "10.1016/j.hoc.2017.11.011",
      "author": "L Strocchio",
      "doi-asserted-by": "publisher",
      "first-page": "317",
      "issue": "2",
      "journal-title": "Hematol Oncol Clin North Am.",
      "key": "329_CR24",
      "unstructured": "Strocchio L, Locatelli F. Hematopoietic stem cell transplantation in thalassemia. Hematol Oncol Clin North Am. 2018;32(2):317–28.",
      "volume": "32",
      "year": "2018"
    },
    {
      "DOI": "10.2217/pgs.14.101",
      "author": "A Gravia",
      "doi-asserted-by": "publisher",
      "first-page": "1355",
      "issue": "10",
      "journal-title": "Pharmacogenomics.",
      "key": "329_CR25",
      "unstructured": "Gravia A, Chondrou V, Sgourou A, Papantoni I, Borg J, Katsila T, et al. Individualizing fetal hemoglobin augmenting therapy for β-type hemoglobinopathies patients. Pharmacogenomics. 2014;15(10):1355–64.",
      "volume": "15",
      "year": "2014"
    },
    {
      "DOI": "10.1007/s40291-019-00386-1",
      "author": "E Katsantoni",
      "doi-asserted-by": "publisher",
      "first-page": "223",
      "issue": "2",
      "journal-title": "Mol Diagn Ther.",
      "key": "329_CR26",
      "unstructured": "Katsantoni E. Omics studies in hemoglobinopathies. Mol Diagn Ther. 2019;23(2):223–34.",
      "volume": "23",
      "year": "2019"
    },
    {
      "DOI": "10.1182/blood-2010-11-316893",
      "author": "A Wilber",
      "doi-asserted-by": "publisher",
      "first-page": "3945",
      "issue": "15",
      "journal-title": "Blood",
      "key": "329_CR27",
      "unstructured": "Wilber A, Nienhuis AW, Persons DA. Transcriptional regulation of fetal to adult hemoglobin switching: new therapeutic opportunities. Blood. 2011;117(15):3945–53.",
      "volume": "117",
      "year": "2011"
    },
    {
      "DOI": "10.1101/cshperspect.a011643",
      "author": "VG Sankaran",
      "doi-asserted-by": "publisher",
      "first-page": "a011643",
      "issue": "1",
      "journal-title": "Cold Spring Harb Perspect Med",
      "key": "329_CR28",
      "unstructured": "Sankaran VG, Orkin SH. The switch from fetal to adult hemoglobin. Cold Spring Harb Perspect Med. 2013;3(1):a011643.",
      "volume": "3",
      "year": "2013"
    },
    {
      "DOI": "10.1101/gad.1212704",
      "author": "N Hay",
      "doi-asserted-by": "publisher",
      "first-page": "1926",
      "issue": "16",
      "journal-title": "Genes Dev",
      "key": "329_CR29",
      "unstructured": "Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004;18(16):1926–45.",
      "volume": "18",
      "year": "2004"
    },
    {
      "DOI": "10.1007/s00277-008-0637-y",
      "author": "U Testa",
      "doi-asserted-by": "publisher",
      "first-page": "505",
      "issue": "6",
      "journal-title": "Ann Hematol.",
      "key": "329_CR30",
      "unstructured": "Testa U. Fetal hemoglobin chemical inducers for treatment of hemoglobinopathies. Ann Hematol. 2009;88(6):505–28.",
      "volume": "88",
      "year": "2009"
    },
    {
      "DOI": "10.1038/nm.3101",
      "author": "L Shi",
      "doi-asserted-by": "publisher",
      "first-page": "291",
      "issue": "3",
      "journal-title": "Nat Med.",
      "key": "329_CR31",
      "unstructured": "Shi L, Cui S, Engel JD, Tanabe O. Lysine-specific demethylase 1 is a therapeutic target for fetal hemoglobin induction. Nat Med. 2013;19(3):291–4.",
      "volume": "19",
      "year": "2013"
    },
    {
      "author": "A Basu",
      "first-page": "5",
      "journal-title": "J Cytol Histol",
      "key": "329_CR32",
      "unstructured": "Basu A, Panja A. Pharmacogenomics of the drugs used for the treatment of thalassemia. J Cytol Histol. 2015;6:5.",
      "volume": "6",
      "year": "2015"
    },
    {
      "DOI": "10.1016/j.hoc.2010.08.001",
      "author": "G Atweh",
      "doi-asserted-by": "publisher",
      "first-page": "1131",
      "issue": "6",
      "journal-title": "Hematol Oncol Clin North Am.",
      "key": "329_CR33",
      "unstructured": "Atweh G, Fathallah H. Pharmacologic induction of fetal hemoglobin production. Hematol Oncol Clin North Am. 2010;24(6):1131–44.",
      "volume": "24",
      "year": "2010"
    },
    {
      "DOI": "10.1016/j.addr.2008.06.002",
      "author": "M Bortolato",
      "doi-asserted-by": "publisher",
      "first-page": "1527",
      "issue": "13-14",
      "journal-title": "Adv Drug Deliv Rev.",
      "key": "329_CR34",
      "unstructured": "Bortolato M, Chen K, Shih JC. Monoamine oxidase inactivation: from pathophysiology to therapeutics. Adv Drug Deliv Rev. 2008;60(13-14):1527–33.",
      "volume": "60",
      "year": "2008"
    },
    {
      "DOI": "10.1073/pnas.1006774107",
      "author": "JE Bradner",
      "doi-asserted-by": "publisher",
      "first-page": "12617",
      "issue": "28",
      "journal-title": "Proc Natl Acad Sci U S A",
      "key": "329_CR35",
      "unstructured": "Bradner JE, Mak R, Tanguturi SK, Mazitschek R, Haggarty SJ, Ross K, et al. Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc Natl Acad Sci U S A. 2010;107(28):12617–22.",
      "volume": "107",
      "year": "2010"
    },
    {
      "key": "329_CR36",
      "unstructured": "European Medicines Agency, EMA. https://www.ema.europa.eu. Assessed Nov 10 2020."
    },
    {
      "key": "329_CR37",
      "unstructured": "US Food and Drug Administration, FDA. https://www.fda.gov. Assessed Nov 10 2020."
    },
    {
      "key": "329_CR38",
      "unstructured": "European Medicine Agency, EMA. Approval of luspatercept. https://www.ema.europa.eu/en/medicines/human/EPAR/reblozyl. Assessed Nov 22 2020"
    },
    {
      "key": "329_CR39",
      "unstructured": "European Medicine Agency, EMA. Approval of voxelotor. EU/3/16/1769. https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3161769. Assessed 22 Nov 2020"
    },
    {
      "key": "329_CR40",
      "unstructured": "FDA approves voxelotor for sickle cell disease. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-voxelotor-sickle-cell-disease Assessed 22 Nov 2020"
    },
    {
      "key": "329_CR41",
      "unstructured": "FDA approves luspatercept-aamt for anemia in adults with MDS, US Food and Drug Administration, FDA. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-luspatercept-aamt-anemia-adults-mds. Assessed 19 Dec 2020"
    },
    {
      "DOI": "10.1177/20406207211001136",
      "author": "AK Glaros",
      "doi-asserted-by": "crossref",
      "first-page": "204062072110011",
      "issue": "12",
      "journal-title": "Ther Adv Hematol",
      "key": "329_CR42",
      "unstructured": "Glaros AK, Razvi R, Shah N, Zaidi AU. Voxelotor: alteration of sickle cell disease pathophysiology by a first-in-class polymerization inhibitor. Ther Adv Hematol. 2021;19(12):20406207211001136.",
      "volume": "19",
      "year": "2021"
    },
    {
      "author": "SM AlDallal",
      "first-page": "e7105",
      "issue": "2",
      "journal-title": "Cureus",
      "key": "329_CR43",
      "unstructured": "AlDallal SM. Voxelotor: a ray of hope for sickle disease. Cureus. 2020;12(2):e7105.",
      "volume": "12",
      "year": "2020"
    },
    {
      "DOI": "10.1056/NEJMoa1903212",
      "author": "E Vichinsky",
      "doi-asserted-by": "publisher",
      "first-page": "509",
      "issue": "6",
      "journal-title": "N Engl J Med",
      "key": "329_CR44",
      "unstructured": "Vichinsky E, Hoppe CC, Ataga KI, Ware RE, Nduba V, El-Beshlawy A, et al. HOPE trial investigators. A phase 3 randomized trial of voxelotor in sickle cell disease. N Engl J Med. 2019;381(6):509–19.",
      "volume": "381",
      "year": "2019"
    },
    {
      "DOI": "10.1182/blood-2019-130767",
      "author": "RE Ware",
      "doi-asserted-by": "publisher",
      "first-page": "1003",
      "issue": "Supplement_1",
      "journal-title": "Blood",
      "key": "329_CR45",
      "unstructured": "Ware RE, Brown C, de Montalembert M, Tonda M, Tong B, Hoppe C, et al. Abboud; concomitant hydroxyurea and voxelotor: results from the HOPE Study. Blood. 2019;134(Supplement_1):1003.",
      "volume": "134",
      "year": "2019"
    },
    {
      "DOI": "10.1182/blood-2018-10-879247",
      "author": "A Piga",
      "doi-asserted-by": "publisher",
      "first-page": "1279",
      "issue": "12",
      "journal-title": "Blood",
      "key": "329_CR46",
      "unstructured": "Piga A, Perrotta S, Gamberini MR, Voskaridou E, Melpignano A, Filosa A, et al. Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia. Blood. 2019;133(12):1279–89.",
      "volume": "133",
      "year": "2019"
    },
    {
      "DOI": "10.1182/blood-2003-01-0117",
      "author": "M Bradai",
      "doi-asserted-by": "publisher",
      "first-page": "1529",
      "issue": "4",
      "journal-title": "Blood",
      "key": "329_CR47",
      "unstructured": "Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, de Montalembert M. Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. Blood. 2003;102(4):1529–30.",
      "volume": "102",
      "year": "2003"
    },
    {
      "DOI": "10.1007/s00277-012-1671-3",
      "author": "M Banan",
      "doi-asserted-by": "publisher",
      "first-page": "289",
      "issue": "3",
      "journal-title": "Ann Hematol.",
      "key": "329_CR48",
      "unstructured": "Banan M. Hydroxyurea treatment in β-thalassemia patients: to respond or not to respond? Ann Hematol. 2013;92(3):289–99.",
      "volume": "92",
      "year": "2013"
    },
    {
      "DOI": "10.1182/blood-2012-10-408021",
      "author": "KM Musallam",
      "doi-asserted-by": "publisher",
      "first-page": "2199",
      "issue": "12",
      "journal-title": "Blood",
      "key": "329_CR49",
      "unstructured": "Musallam KM, Taher AT, Cappellini MD, Sankaran VG. Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia. Blood. 2013;121(12):2199–212.",
      "volume": "121",
      "year": "2013"
    },
    {
      "DOI": "10.1182/blood-2015-03-633594",
      "author": "S Mettananda",
      "doi-asserted-by": "publisher",
      "first-page": "3694",
      "issue": "24",
      "journal-title": "Blood",
      "key": "329_CR50",
      "unstructured": "Mettananda S, Gibbons RJ, Higgs DR. α-Globin as a molecular target in the treatment of β-thalassemia. Blood. 2015;125(24):3694–701.",
      "volume": "125",
      "year": "2015"
    },
    {
      "DOI": "10.4081/hr.2016.6678",
      "author": "S Sclafani",
      "doi-asserted-by": "publisher",
      "first-page": "6678",
      "issue": "4",
      "journal-title": "Hematol Rep.",
      "key": "329_CR51",
      "unstructured": "Sclafani S, Pecoraro A, Agrigento V, Troia A, Di Maggio R, Sacco M, et al. Study on hydroxyurea response in hemoglobinopathies patients using genetic markers and liquid erythroid cultures. Hematol Rep. 2016;8(4):6678.",
      "volume": "8",
      "year": "2016"
    },
    {
      "DOI": "10.1007/978-1-4939-7299-9_7",
      "author": "S Cui",
      "doi-asserted-by": "publisher",
      "first-page": "177",
      "journal-title": "Adv Exp Med Biol.",
      "key": "329_CR52",
      "unstructured": "Cui S, Engel JD. Reactivation of fetal hemoglobin for treating β-thalassemia and sickle cell disease. Adv Exp Med Biol. 2017;1013:177–202.",
      "volume": "1013",
      "year": "2017"
    },
    {
      "DOI": "10.1038/pr.2013.227",
      "author": "NS Green",
      "doi-asserted-by": "publisher",
      "first-page": "196",
      "issue": "1-2",
      "journal-title": "Pediatr Res.",
      "key": "329_CR53",
      "unstructured": "Green NS, Barral S. Emerging science of hydroxyurea therapy for pediatric sickle cell disease. Pediatr Res. 2014;75(1-2):196–204.",
      "volume": "75",
      "year": "2014"
    },
    {
      "DOI": "10.1080/03630260701680367",
      "author": "GP Patrinos",
      "doi-asserted-by": "publisher",
      "first-page": "229",
      "issue": "1-2",
      "journal-title": "Hemoglobin.",
      "key": "329_CR54",
      "unstructured": "Patrinos GP, Grosveld FG. Pharmacogenomics and therapeutics of hemoglobinopathies. Hemoglobin. 2008;32(1-2):229–36.",
      "volume": "32",
      "year": "2008"
    },
    {
      "DOI": "10.2217/pgs.13.81",
      "author": "T Burt",
      "doi-asserted-by": "publisher",
      "first-page": "1085",
      "issue": "9",
      "journal-title": "Pharmacogenomics.",
      "key": "329_CR55",
      "unstructured": "Burt T, Dhillon S. Pharmacogenomics in early-phase clinical development. Pharmacogenomics. 2013;14(9):1085–97.",
      "volume": "14",
      "year": "2013"
    },
    {
      "author": "KR Crews",
      "first-page": "467",
      "issue": "4",
      "journal-title": "Clin Pharmacol Ther.",
      "key": "329_CR56",
      "unstructured": "Crews KR, Hicks JK, Pui CH, Relling MV, Evans WE. Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther. 2012;92(4):467–75.",
      "volume": "92",
      "year": "2012"
    },
    {
      "DOI": "10.1073/pnas.0804799105",
      "author": "G Lettre",
      "doi-asserted-by": "publisher",
      "first-page": "11869",
      "issue": "33",
      "journal-title": "Proc Natl Acad Sci U S A.",
      "key": "329_CR57",
      "unstructured": "Lettre G, Sankaran VG, Bezerra MA, Araújo AS, Uda M, Sanna S, et al. DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proc Natl Acad Sci U S A. 2008;105(33):11869–74.",
      "volume": "105",
      "year": "2008"
    },
    {
      "DOI": "10.1126/science.1165409",
      "author": "VG Sankaran",
      "doi-asserted-by": "publisher",
      "first-page": "1839",
      "issue": "5909",
      "journal-title": "Science.",
      "key": "329_CR58",
      "unstructured": "Sankaran VG, Menne TF, Xu J, Akie TE, Lettre G, Van Handel B, et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science. 2008;322(5909):1839–42.",
      "volume": "322",
      "year": "2008"
    },
    {
      "DOI": "10.1073/pnas.0611393104",
      "author": "SL Thein",
      "doi-asserted-by": "publisher",
      "first-page": "11346",
      "issue": "27",
      "journal-title": "Proc Natl Acad Sci U S A.",
      "key": "329_CR59",
      "unstructured": "Thein SL, Menzel S, Peng X, Best S, Jiang J, Close J, et al. Intergenic variants of HBS1L-MYB are responsible for a major quantitative trait locus on chromosome 6q23 influencing fetal hemoglobin levels in adults. Proc Natl Acad Sci U S A. 2007;104(27):11346–51.",
      "volume": "104",
      "year": "2007"
    },
    {
      "DOI": "10.1038/ng.707",
      "author": "G Galarneau",
      "doi-asserted-by": "publisher",
      "first-page": "1049",
      "issue": "12",
      "journal-title": "Nat Genet.",
      "key": "329_CR60",
      "unstructured": "Galarneau G, Palmer CD, Sankaran VG, Orkin SH, Hirschhorn JN, Lettre G. Fine-mapping at three loci known to affect fetal hemoglobin levels explains additional genetic variation. Nat Genet. 2010;42(12):1049–51.",
      "volume": "42",
      "year": "2010"
    },
    {
      "DOI": "10.1038/ng2108",
      "author": "S Menzel",
      "doi-asserted-by": "publisher",
      "first-page": "1197",
      "issue": "10",
      "journal-title": "Nat Genet.",
      "key": "329_CR61",
      "unstructured": "Menzel S, Garner C, Gut I, Matsuda F, Yamaguchi M, Heath S, et al. A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15. Nat Genet. 2007;39(10):1197–9.",
      "volume": "39",
      "year": "2007"
    },
    {
      "DOI": "10.1128/MCB.00035-15",
      "author": "YC Chou",
      "doi-asserted-by": "publisher",
      "first-page": "2541",
      "issue": "14",
      "journal-title": "Mol Cell Biol.",
      "key": "329_CR62",
      "unstructured": "Chou YC, Chen RL, Lai ZS, Song JS, Chao YS, Shen CK. Pharmacological induction of human fetal globin gene in hydroxyurea-resistant primary adult erythroid cells. Mol Cell Biol. 2015;35(14):2541–53.",
      "volume": "35",
      "year": "2015"
    },
    {
      "DOI": "10.2217/pgs-2019-0063",
      "author": "A Stratopoulos",
      "doi-asserted-by": "publisher",
      "first-page": "791",
      "issue": "11",
      "journal-title": "Pharmacogenomics.",
      "key": "329_CR63",
      "unstructured": "Stratopoulos A, Kolliopoulou A, Karamperis K, John A, Kydonopoulou K, Esftathiou G, et al. Genomic variants in members of the Krüppel-like factor gene family are associated with disease severity and hydroxyurea treatment efficacy in β-hemoglobinopathies patients. Pharmacogenomics. 2019;20(11):791–801.",
      "volume": "20",
      "year": "2019"
    },
    {
      "DOI": "10.1186/s40246-017-0120-8",
      "author": "V Chondrou",
      "doi-asserted-by": "publisher",
      "first-page": "24",
      "issue": "1",
      "journal-title": "Hum Genomics.",
      "key": "329_CR64",
      "unstructured": "Chondrou V, Kolovos P, Sgourou A, Kourakli A, Pavlidaki A, Kastrinou V, et al. Whole transcriptome analysis of human erythropoietic cells during ontogenesis suggests a role of VEGFA gene as modulator of fetal hemoglobin and pharmacogenomic biomarker of treatment response to hydroxyurea in β-type hemoglobinopathy patients. Hum Genomics. 2017;11(1):24.",
      "volume": "11",
      "year": "2017"
    },
    {
      "DOI": "10.1186/s12920-015-0120-2",
      "author": "DA Ngo",
      "doi-asserted-by": "publisher",
      "first-page": "44",
      "issue": "8",
      "journal-title": "BMC Med Genomics",
      "key": "329_CR65",
      "unstructured": "Ngo DA, Steinberg MH. Genomic approaches to identifying targets for treating β hemoglobinopathies. BMC Med Genomics. 2015;29(8):44.",
      "volume": "29",
      "year": "2015"
    },
    {
      "DOI": "10.1038/s41397-018-0045-1",
      "author": "SCMA Yahouédéhou",
      "doi-asserted-by": "publisher",
      "first-page": "730",
      "issue": "6",
      "journal-title": "Pharmacogenomics J.",
      "key": "329_CR66",
      "unstructured": "Yahouédéhou SCMA, Adorno EV, da Guarda CC, Ndidi US, Carvalho SP, Santiago RP, et al. Hydroxyurea in the management of sickle cell disease: pharmacogenomics and enzymatic metabolism. Pharmacogenomics J. 2018;18(6):730–9.",
      "volume": "18",
      "year": "2018"
    },
    {
      "DOI": "10.1371/journal.pone.0055709",
      "author": "NS Green",
      "doi-asserted-by": "publisher",
      "first-page": "e55709",
      "issue": "2",
      "journal-title": "Plos One.",
      "key": "329_CR67",
      "unstructured": "Green NS, Ender KL, Pashankar F, Driscoll C, Giardina PJ, Mullen CA, et al. Candidate sequence variants and fetal hemoglobin in children with sickle cell disease treated with hydroxyurea. Plos One. 2013;8(2):e55709.",
      "volume": "8",
      "year": "2013"
    },
    {
      "DOI": "10.1038/sj.tpj.6500433",
      "author": "Q Ma",
      "doi-asserted-by": "publisher",
      "first-page": "386",
      "issue": "6",
      "journal-title": "Pharmacogenomics J.",
      "key": "329_CR68",
      "unstructured": "Ma Q, Wyszynski DF, Farrell JJ, Kutlar A, Farrer LA, Baldwin CT, et al. Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea. Pharmacogenomics J. 2007;7(6):386–94.",
      "volume": "7",
      "year": "2007"
    },
    {
      "DOI": "10.1080/03630269.2019.1597732",
      "author": "A Kolliopoulou",
      "doi-asserted-by": "publisher",
      "first-page": "27",
      "issue": "1",
      "journal-title": "Hemoglobin.",
      "key": "329_CR69",
      "unstructured": "Kolliopoulou A, Siamoglou S, John A, Sgourou A, Kourakli A, Symeonidis A, et al. Role of genomic biomarkers in increasing fetal hemoglobin levels upon hydroxyurea therapy and in β-thalassemia intermedia: a validation cohort study. Hemoglobin. 2019;43(1):27–33.",
      "volume": "43",
      "year": "2019"
    },
    {
      "DOI": "10.2217/pgs.12.125",
      "author": "J Borg",
      "doi-asserted-by": "publisher",
      "first-page": "1487",
      "issue": "13",
      "journal-title": "Pharmacogenomics.",
      "key": "329_CR70",
      "unstructured": "Borg J, Phylactides M, Bartsakoulia M, Tafrali C, Lederer C, Felice AE, et al. KLF10 gene expression is associated with high fetal hemoglobin levels and with response to hydroxyurea treatment in β-hemoglobinopathy patients. Pharmacogenomics. 2012;13(13):1487–500.",
      "volume": "13",
      "year": "2012"
    },
    {
      "DOI": "10.1097/MPH.0000000000000762",
      "author": "MS Elalfy",
      "doi-asserted-by": "publisher",
      "first-page": "e155",
      "issue": "3",
      "journal-title": "J Pediatr Hematol Oncol.",
      "key": "329_CR71",
      "unstructured": "Elalfy MS, El Sherif NH, Kamal TM, Aly NH. Klf10 Gene, a secondary modifier and a pharmacogenomic biomarker of hydroxyurea treatment among patients with hemoglobinopathies. J Pediatr Hematol Oncol. 2017;39(3):e155–62.",
      "volume": "39",
      "year": "2017"
    },
    {
      "DOI": "10.1038/nrg2554",
      "author": "KA Frazer",
      "doi-asserted-by": "publisher",
      "first-page": "241",
      "issue": "4",
      "journal-title": "Nat Rev Genet.",
      "key": "329_CR72",
      "unstructured": "Frazer KA, Murray SS, Schork NJ, Topol EJ. Human genetic variation and its contribution to complex traits. Nat Rev Genet. 2009;10(4):241–51.",
      "volume": "10",
      "year": "2009"
    },
    {
      "DOI": "10.1038/nrg.2015.36",
      "author": "WS Bush",
      "doi-asserted-by": "publisher",
      "first-page": "129",
      "issue": "3",
      "journal-title": "Nat Rev Genet.",
      "key": "329_CR73",
      "unstructured": "Bush WS, Oetjens MT, Crawford DC. Unravelling the human genome-phenome relationship using phenome-wide association studies. Nat Rev Genet. 2016;17(3):129–45.",
      "volume": "17",
      "year": "2016"
    },
    {
      "DOI": "10.2217/pgs.15.121",
      "author": "MR Luizon",
      "doi-asserted-by": "publisher",
      "first-page": "1829",
      "issue": "16",
      "journal-title": "Pharmacogenomics.",
      "key": "329_CR74",
      "unstructured": "Luizon MR, Ahituv N. Uncovering drug-responsive regulatory elements. Pharmacogenomics. 2015;16(16):1829–41.",
      "volume": "16",
      "year": "2015"
    },
    {
      "DOI": "10.1016/j.drudis.2017.12.002",
      "author": "G Singh",
      "doi-asserted-by": "publisher",
      "first-page": "652",
      "issue": "3",
      "journal-title": "Drug Discov Today.",
      "key": "329_CR75",
      "unstructured": "Singh G, Schulthess D, Hughes N, Vannieuwenhuyse B, Kalra D. Real world big data for clinical research and drug development. Drug Discov Today. 2018;23(3):652–60.",
      "volume": "23",
      "year": "2018"
    },
    {
      "DOI": "10.1101/gr.9.8.677",
      "author": "ST Sherry",
      "doi-asserted-by": "publisher",
      "first-page": "677",
      "journal-title": "Genome Res",
      "key": "329_CR76",
      "unstructured": "Sherry ST, Ward M, Sirotkin K. dbSNP—database for single nucleotide polymorphisms and other classes of minor genetic variation. Genome Res. 1999;9:677–9.",
      "volume": "9",
      "year": "1999"
    },
    {
      "DOI": "10.2217/pgs.13.31",
      "author": "C Tafrali",
      "doi-asserted-by": "publisher",
      "first-page": "469",
      "issue": "5",
      "journal-title": "Pharmacogenomics.",
      "key": "329_CR77",
      "unstructured": "Tafrali C, Paizi A, Borg J, Radmilovic M, Bartsakoulia M, Giannopoulou E, et al. Genomic variation in the MAP3K5 gene is associated with β-thalassemia disease severity and hydroxyurea treatment efficacy. Pharmacogenomics. 2013;14(5):469–83.",
      "volume": "14",
      "year": "2013"
    },
    {
      "DOI": "10.1016/j.cca.2009.06.019",
      "author": "KY Italia",
      "doi-asserted-by": "publisher",
      "first-page": "10",
      "issue": "1-2",
      "journal-title": "Clin Chim Acta.",
      "key": "329_CR78",
      "unstructured": "Italia KY, Jijina FJ, Merchant R, Panjwani S, Nadkarni AH, Sawant PM, et al. Response to hydroxyurea in beta thalassemia major and intermedia: experience in western India. Clin Chim Acta. 2009;407(1-2):10–5.",
      "volume": "407",
      "year": "2009"
    },
    {
      "author": "MH Steinberg",
      "first-page": "8",
      "issue": "3 Suppl 3",
      "journal-title": "Semin Hematol.",
      "key": "329_CR79",
      "unstructured": "Steinberg MH. Fetal hemoglobin in sickle cell anemia: determinants of fetal hemoglobin response to hydroxyurea. Semin Hematol. 1997;34(3 Suppl 3):8–14.",
      "volume": "34",
      "year": "1997"
    },
    {
      "DOI": "10.1007/s00277-003-0836-5",
      "author": "M Alebouyeh",
      "doi-asserted-by": "publisher",
      "first-page": "430",
      "issue": "7",
      "journal-title": "Ann Hematol.",
      "key": "329_CR80",
      "unstructured": "Alebouyeh M, Moussavi F, Haddad-Deylami H, Vossough P. Hydroxyurea in the treatment of major beta-thalassemia and importance of genetic screening. Ann Hematol. 2004;83(7):430–3.",
      "volume": "83",
      "year": "2004"
    },
    {
      "author": "M Yavarian",
      "first-page": "1172",
      "issue": "10",
      "journal-title": "Haematologica.",
      "key": "329_CR81",
      "unstructured": "Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC. Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. Haematologica. 2004;89(10):1172–8.",
      "volume": "89",
      "year": "2004"
    },
    {
      "DOI": "10.1097/MPH.0b013e31827e8662",
      "author": "SH Ansari",
      "doi-asserted-by": "publisher",
      "first-page": "e153",
      "issue": "4",
      "journal-title": "J Pediatr Hematol Oncol.",
      "key": "329_CR82",
      "unstructured": "Ansari SH, Shamsi TS, Munzir S, Khan MT, Erum S, Perveen K, et al. Gγ-Xmn I polymorphism: a significant determinant of β-thalassemia treatment without blood transfusion. J Pediatr Hematol Oncol. 2013;35(4):e153–6.",
      "volume": "35",
      "year": "2013"
    },
    {
      "DOI": "10.1111/j.1537-2995.2007.01399.x",
      "author": "M Bradai",
      "doi-asserted-by": "publisher",
      "first-page": "1830",
      "issue": "10",
      "journal-title": "Transfusion.",
      "key": "329_CR83",
      "unstructured": "Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, et al. Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. Transfusion. 2007;47(10):1830–6.",
      "volume": "47",
      "year": "2007"
    },
    {
      "DOI": "10.1002/ajh.21120",
      "author": "A Koren",
      "doi-asserted-by": "publisher",
      "first-page": "366",
      "issue": "5",
      "journal-title": "Am J Hematol.",
      "key": "329_CR84",
      "unstructured": "Koren A, Levin C, Dgany O, Kransnov T, Elhasid R, Zalman L, et al. Response to hydroxyurea therapy in beta-thalassemia. Am J Hematol. 2008;83(5):366–70.",
      "volume": "83",
      "year": "2008"
    },
    {
      "DOI": "10.1007/s00277-005-1026-4",
      "author": "A Dixit",
      "doi-asserted-by": "publisher",
      "first-page": "441",
      "issue": "7",
      "journal-title": "Ann Hematol.",
      "key": "329_CR85",
      "unstructured": "Dixit A, Chatterjee TC, Mishra P, Choudhry DR, Mahapatra M, Tyagi S, et al. Hydroxyurea in thalassemia intermedia—a promising therapy. Ann Hematol. 2005;84(7):441–6.",
      "volume": "84",
      "year": "2005"
    },
    {
      "DOI": "10.3109/03630269.2012.691147",
      "author": "M Banan",
      "doi-asserted-by": "publisher",
      "first-page": "371",
      "issue": "4",
      "journal-title": "Hemoglobin.",
      "key": "329_CR86",
      "unstructured": "Banan M, Bayat H, Azarkeivan A, Mohammadparast S, Kamali K, Farashi S, et al. The XmnI and BCL11A single nucleotide polymorphisms may help predict hydroxyurea response in Iranian β-thalassemia patients. Hemoglobin. 2012;36(4):371–80.",
      "volume": "36",
      "year": "2012"
    },
    {
      "DOI": "10.1111/j.1365-2141.2010.08397.x",
      "author": "P Rigano",
      "doi-asserted-by": "publisher",
      "first-page": "509",
      "issue": "5",
      "journal-title": "Br J Haematol.",
      "key": "329_CR87",
      "unstructured": "Rigano P, Pecoraro A, Calzolari R, Troia A, Acuto S, Renda D, et al. Desensitization to hydroxycarbamide following long-term treatment of thalassaemia intermedia as observed in vivo and in primary erythroid cultures from treated patients. Br J Haematol. 2010;151(5):509–15.",
      "volume": "151",
      "year": "2010"
    },
    {
      "DOI": "10.1007/s12185-011-0985-6",
      "author": "M Karimi",
      "doi-asserted-by": "publisher",
      "first-page": "51",
      "issue": "1",
      "journal-title": "Int J Hematol.",
      "key": "329_CR88",
      "unstructured": "Karimi M, Haghpanah S, Farhadi A, Yavarian M. Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. Int J Hematol. 2012;95(1):51–6.",
      "volume": "95",
      "year": "2012"
    },
    {
      "DOI": "10.2217/pgs-2016-0076",
      "author": "A Gravia",
      "doi-asserted-by": "publisher",
      "first-page": "1785",
      "issue": "16",
      "journal-title": "Pharmacogenomics.",
      "key": "329_CR89",
      "unstructured": "Gravia A, Chondrou V, Kolliopoulou A, Kourakli A, John A, Symeonidis A, et al. Correlation of SIN3A genomic variants with β-hemoglobinopathies disease severity and hydroxyurea treatment efficacy. Pharmacogenomics. 2016;17(16):1785–93.",
      "volume": "17",
      "year": "2016"
    },
    {
      "DOI": "10.1093/hmg/ddw170",
      "author": "EC Smith",
      "doi-asserted-by": "publisher",
      "first-page": "R99",
      "issue": "R2",
      "journal-title": "Hum Mol Genet.",
      "key": "329_CR90",
      "unstructured": "Smith EC, Orkin SH. Hemoglobin genetics: recent contributions of GWAS and gene editing. Hum Mol Genet. 2016;25(R2):R99–R105.",
      "volume": "25",
      "year": "2016"
    },
    {
      "DOI": "10.1002/jcb.27253",
      "author": "L Shariati",
      "doi-asserted-by": "publisher",
      "first-page": "9357",
      "issue": "11",
      "journal-title": "J Cell Biochem.",
      "key": "329_CR91",
      "unstructured": "Shariati L, Rohani F, Heidari Hafshejani N, Kouhpayeh S, Boshtam M, Mirian M, et al. Disruption of SOX6 gene using CRISPR/Cas9 technology for gamma-globin reactivation: an approach towards gene therapy of β-thalassemia. J Cell Biochem. 2018;119(11):9357–63.",
      "volume": "119",
      "year": "2018"
    },
    {
      "DOI": "10.1128/MCB.00714-14",
      "author": "M Suzuki",
      "doi-asserted-by": "publisher",
      "first-page": "3560",
      "issue": "19",
      "journal-title": "Mol Cell Biol",
      "key": "329_CR92",
      "unstructured": "Suzuki M, Yamamoto M, Engel JD. Fetal globin gene repressors as drug targets for molecular therapies to treat the β-globinopathies. Mol Cell Biol. 2014;34(19):3560–9.",
      "volume": "34",
      "year": "2014"
    },
    {
      "DOI": "10.1038/s41588-018-0085-0",
      "author": "GE Martyn",
      "doi-asserted-by": "publisher",
      "first-page": "498",
      "issue": "4",
      "journal-title": "Nat Genet.",
      "key": "329_CR93",
      "unstructured": "Martyn GE, Wienert B, Yang L, Shah M, Norton LJ, Burdach J, et al. Natural regulatory mutations elevate the fetal globin gene via disruption of BCL11A or ZBTB7A binding. Nat Genet. 2018;50(4):498–503.",
      "volume": "50",
      "year": "2018"
    },
    {
      "DOI": "10.1080/23808993.2019.1617632",
      "author": "T Qian",
      "doi-asserted-by": "publisher",
      "first-page": "189",
      "issue": "3",
      "journal-title": "Expert Rev Precis Med Drug Dev.",
      "key": "329_CR94",
      "unstructured": "Qian T, Zhu S, Hoshida Y. Use of big data in drug development for precision medicine: an update. Expert Rev Precis Med Drug Dev. 2019;4(3):189–200.",
      "volume": "4",
      "year": "2019"
    },
    {
      "DOI": "10.3109/03630269809092136",
      "author": "RC Hardison",
      "doi-asserted-by": "publisher",
      "first-page": "113",
      "issue": "2",
      "journal-title": "Hemoglobin.",
      "key": "329_CR95",
      "unstructured": "Hardison RC, Chui DH, Riemer CR, Miller W, Carver MF, Molchanova TP, et al. Access to a syllabus of human hemoglobin variants (1996) via the World Wide Web. Hemoglobin. 1998;22(2):113–27.",
      "volume": "22",
      "year": "1998"
    },
    {
      "DOI": "10.1081/HEM-100104027",
      "author": "RC Hardison",
      "doi-asserted-by": "publisher",
      "first-page": "183",
      "issue": "2",
      "journal-title": "Hemoglobin.",
      "key": "329_CR96",
      "unstructured": "Hardison RC, Chui DH, Riemer C, Giardine B, Lehväslaiho H, Wajcman H, et al. Databases of human hemoglobin variants and other resources at the globin gene server. Hemoglobin. 2001;25(2):183–93.",
      "volume": "25",
      "year": "2001"
    },
    {
      "key": "329_CR97",
      "unstructured": "HbVar: a database of human hemoglobin variants and thalassemias. Globin Gene Server. Pensylvania State University, Pensylvania.2012. http://globin.bx.psu.edu/hbvar/. Accessed 06 Nov 2020."
    },
    {
      "DOI": "10.1093/nar/gkt911",
      "author": "B Giardine",
      "doi-asserted-by": "publisher",
      "first-page": "D1063",
      "issue": "Database issue",
      "journal-title": "Nucleic Acids Res.",
      "key": "329_CR98",
      "unstructured": "Giardine B, Borg J, Viennas E, Pavlidis C, Moradkhani K, Joly P, et al. Updates of the HbVar database of human hemoglobin variants and thalassemia mutations. Nucleic Acids Res. 2014;42(Database issue):D1063–9.",
      "volume": "42",
      "year": "2014"
    },
    {
      "DOI": "10.1093/nar/gkaa959",
      "doi-asserted-by": "crossref",
      "key": "329_CR99",
      "unstructured": "Giardine BM, Joly P, Pissard S, Wajcman H, K Chui DH, Hardison RC, Patrinos GP. Clinically relevant updates of the HbVar database of human hemoglobin variants and thalassemia mutations. Nucleic Acids Res. 2021;49(D1):D1192-D1196."
    },
    {
      "DOI": "10.1002/humu.24018",
      "author": "F Kounelis",
      "doi-asserted-by": "publisher",
      "first-page": "1112",
      "issue": "6",
      "journal-title": "Hum Mutat.",
      "key": "329_CR100",
      "unstructured": "Kounelis F, Kanterakis A, Kanavos A, Pandi MT, Kordou Z, Manusama O, et al. Documentation of clinically relevant genomic biomarker allele frequencies in the next-generation FINDbase worldwide database. Hum Mutat. 2020;41(6):1112–22.",
      "volume": "41",
      "year": "2020"
    },
    {
      "key": "329_CR101",
      "unstructured": "FINDbase. University of Patras, Patras 2006. http://www.findbase.org. Accessed 10 Nov 2020. No Title."
    },
    {
      "key": "329_CR102",
      "unstructured": "Leiden Open Variation Database (LOVD). University of Leiden, Leiden. 2004. http://www.lovd.nl. Accessed 10 Nov 2020."
    },
    {
      "DOI": "10.1002/humu.21343",
      "author": "AA Out",
      "doi-asserted-by": "publisher",
      "first-page": "1205",
      "journal-title": "Hum Mutat",
      "key": "329_CR103",
      "unstructured": "Out AA, Tops CMJ, Nielsen M, Weiss MM, Van Minderhout IJHM, Fokkema IFAC, et al. Leiden open variation database of the MUTYH gene. Hum Mutat. 2010;31:1205–15.",
      "volume": "31",
      "year": "2010"
    },
    {
      "DOI": "10.1038/ng.785",
      "author": "B Giardine",
      "doi-asserted-by": "publisher",
      "first-page": "295",
      "journal-title": "Nat Genet",
      "key": "329_CR104",
      "unstructured": "Giardine B, Borg J, Higgs DR, Peterson KR, Philipsen S, Maglott D, et al. Systematic documentation and analysis of human genetic variation in hemoglobinopathies using the microattribution approach. Nat Genet. 2011;43:295–302.",
      "volume": "43",
      "year": "2011"
    },
    {
      "DOI": "10.1155/2019/9210841",
      "author": "T Qadah",
      "doi-asserted-by": "publisher",
      "first-page": "9210841",
      "journal-title": "Biomed Res Int.",
      "key": "329_CR105",
      "unstructured": "Qadah T, Jamal MS. Computational analysis of protein structure changes as a result of nondeletion insertion mutations in human β-globin gene suggests possible cause of β-thalassemia. Biomed Res Int. 2019;2019:9210841.",
      "volume": "2019",
      "year": "2019"
    },
    {
      "key": "329_CR106",
      "unstructured": "ClinVar. National Center for Biotechnology Information \u0026 U.S. National Library of Medicine, Rockville Pike. 2012. https://www.ncbi.nlm.nih.gov/clinvar/. Accessed 01 Dec 2020."
    },
    {
      "key": "329_CR107",
      "unstructured": "Online Mendelian Inheritance in Man (OMIM), Johns Hopkins University.1966. https://www.omim.org/. Accessed 02 Dec 2020."
    },
    {
      "DOI": "10.1093/nar/gkv1222",
      "author": "MJ Landrum",
      "doi-asserted-by": "publisher",
      "first-page": "D862",
      "journal-title": "Nucleic Acids Res",
      "key": "329_CR108",
      "unstructured": "Landrum MJ, Lee JM, Benson M, Brown G, Chao C, Chitipiralla S, et al. ClinVar: Public archive of interpretations of clinically relevant variants. Nucleic Acids Res. 2016;44:D862–8.",
      "volume": "44",
      "year": "2016"
    },
    {
      "DOI": "10.1002/humu.23641",
      "author": "MJ Landrum",
      "doi-asserted-by": "publisher",
      "first-page": "1623",
      "journal-title": "Hum Mutat",
      "key": "329_CR109",
      "unstructured": "Landrum MJ, Kattman BL. ClinVar at five years: delivering on the promise. Hum Mutat. 2018;39:1623–30.",
      "volume": "39",
      "year": "2018"
    },
    {
      "key": "329_CR110",
      "unstructured": "1000 Genome database project, EMBL-EBI. 2008. https://www.interna-tionalgenome.org. Accessed 13 Dec 2020."
    },
    {
      "DOI": "10.1371/journal.pone.0174637",
      "author": "T Carlice-Dos-Reis",
      "doi-asserted-by": "publisher",
      "first-page": "e0174637",
      "issue": "4",
      "journal-title": "Plos One.",
      "key": "329_CR111",
      "unstructured": "Carlice-Dos-Reis T, Viana J, Moreira FC, Cardoso GL, Guerreiro J, Santos S, et al. Investigation of mutations in the HBB gene using the 1,000 genomes database. Plos One. 2017;12(4):e0174637.",
      "volume": "12",
      "year": "2017"
    },
    {
      "DOI": "10.1093/hmg/ddz172",
      "author": "Y Ikawa",
      "doi-asserted-by": "publisher",
      "first-page": "R24",
      "issue": "R1",
      "journal-title": "Hum Mol Genet.",
      "key": "329_CR112",
      "unstructured": "Ikawa Y, Miccio A, Magrin E, Kwiatkowski JL, Rivella S, Cavazzana M. Gene therapy of hemoglobinopathies: progress and future challenges. Hum Mol Genet. 2019;28(R1):R24–30.",
      "volume": "28",
      "year": "2019"
    },
    {
      "DOI": "10.1016/j.crvi.2016.04.011",
      "author": "A Fischer",
      "doi-asserted-by": "publisher",
      "first-page": "314",
      "issue": "7-8",
      "journal-title": "C R Biol.",
      "key": "329_CR113",
      "unstructured": "Fischer A. Gene therapy: Myth or reality? C R Biol. 2016;339(7-8):314–8.",
      "volume": "339",
      "year": "2016"
    },
    {
      "DOI": "10.1007/s00439-016-1696-0",
      "author": "RN Cottle",
      "doi-asserted-by": "publisher",
      "first-page": "993",
      "issue": "9",
      "journal-title": "Hum Genet.",
      "key": "329_CR114",
      "unstructured": "Cottle RN, Lee CM, Bao G. Treating hemoglobinopathies using gene-correction approaches: promises and challenges. Hum Genet. 2016;135(9):993–1010.",
      "volume": "135",
      "year": "2016"
    },
    {
      "DOI": "10.1182/asheducation-2009.1.690",
      "doi-asserted-by": "crossref",
      "key": "329_CR115",
      "unstructured": "Persons DA. Hematopoietic stem cell gene transfer for the treatment of hemoglobin disorders. Hematol Am Soc Hematol Educ Program. 2009;(1):690–7."
    },
    {
      "DOI": "10.2174/156652306779010660",
      "author": "L Zhong",
      "doi-asserted-by": "publisher",
      "first-page": "683",
      "issue": "6",
      "journal-title": "Curr Gene Ther.",
      "key": "329_CR116",
      "unstructured": "Zhong L, Zhao W, Wu J, Maina N, Han Z, Srivastava A. Adeno-associated virus-mediated gene transfer in hematopoietic stem/ progenitor cells as a therapeutic tool. Curr Gene Ther. 2006;6(6):683–98.",
      "volume": "6",
      "year": "2006"
    },
    {
      "DOI": "10.1016/j.hoc.2013.12.003",
      "author": "S Chandrakasan",
      "doi-asserted-by": "publisher",
      "first-page": "199",
      "issue": "2",
      "journal-title": "Hematol Oncol Clin North Am.",
      "key": "329_CR117",
      "unstructured": "Chandrakasan S, Malik P. Gene therapy for hemoglobinopathies: the state of the field and the future. Hematol Oncol Clin North Am. 2014;28(2):199–216.",
      "volume": "28",
      "year": "2014"
    },
    {
      "DOI": "10.5772/intechopen.76496",
      "doi-asserted-by": "crossref",
      "key": "329_CR118",
      "unstructured": "Aldemir Ö. The genetic aspect of thalassemia: from diagnosis to treatment. Thalassemia and Other Hemolytic Anemias InTechOpen. 2018;1:11–28. Available from: https://www.intechopen.com/books/thalassemia-and-other-hemolytic-anemias/the-genetic-aspect-of-thalassemia-from-diagnosis-to-treatment."
    },
    {
      "DOI": "10.1007/978-3-540-37654-5",
      "doi-asserted-by": "publisher",
      "key": "329_CR119",
      "unstructured": "Patrinos GP, Antonarakis SE. Human hemoglobin. Vogel and Motulsky’s human genetics: problems and approaches (Fourth Edition). Heidelberg: Springer-Verlag; 2010. p. 365–401. https://doi.org/10.1007/978-3-540-37654-5."
    },
    {
      "DOI": "10.1177/2040620716653729",
      "author": "MA Goodman",
      "doi-asserted-by": "publisher",
      "first-page": "302",
      "issue": "5",
      "journal-title": "Ther Adv Hematol.",
      "key": "329_CR120",
      "unstructured": "Goodman MA, Malik P. The potential of gene therapy approaches for the treatment of hemoglobinopathies: achievements and challenges. Ther Adv Hematol. 2016;7(5):302–15.",
      "volume": "7",
      "year": "2016"
    },
    {
      "author": "M Ramamoorth",
      "first-page": "GE01",
      "issue": "1",
      "journal-title": "J Clin Diagn Res.",
      "key": "329_CR121",
      "unstructured": "Ramamoorth M, Narvekar A. Non viral vectors in gene therapy—an overview. J Clin Diagn Res. 2015;9(1):GE01–6.",
      "volume": "9",
      "year": "2015"
    },
    {
      "author": "K Lundstrom",
      "first-page": "42",
      "issue": "2",
      "journal-title": "Viral Vectors in Gene Therapy. Diseases.",
      "key": "329_CR122",
      "unstructured": "Lundstrom K. Viral Vectors in Gene Therapy Diseases. 2018;6(2):42.",
      "volume": "6",
      "year": "2018"
    },
    {
      "DOI": "10.1182/blood-2002-02-0599",
      "author": "FE Nicolini",
      "doi-asserted-by": "publisher",
      "first-page": "1257",
      "issue": "4",
      "journal-title": "Blood.",
      "key": "329_CR123",
      "unstructured": "Nicolini FE, Imren S, Oh IH, Humphries RK, Leboulch P, Fabry ME, et al. Expression of a human beta-globin transgene in erythroid cells derived from retrovirally transduced transplantable human fetal liver and cord blood cells. Blood. 2002;100(4):1257–64.",
      "volume": "100",
      "year": "2002"
    },
    {
      "DOI": "10.1182/blood.V81.5.1384.1384",
      "author": "I Plavec",
      "doi-asserted-by": "publisher",
      "first-page": "1384",
      "issue": "5",
      "journal-title": "Blood.",
      "key": "329_CR124",
      "unstructured": "Plavec I, Papayannopoulou T, Maury C, Meyer F. A human beta-globin gene fused to the human beta-globin locus control region is expressed at high levels in erythroid cells of mice engrafted with retrovirus-transduced hematopoietic stem cells. Blood. 1993;81(5):1384–92.",
      "volume": "81",
      "year": "1993"
    },
    {
      "DOI": "10.1038/331035a0",
      "author": "EA Dzierzak",
      "doi-asserted-by": "publisher",
      "first-page": "35",
      "issue": "6151",
      "journal-title": "Nature.",
      "key": "329_CR125",
      "unstructured": "Dzierzak EA, Papayannopoulou T, Mulligan RC. Lineage-specific expression of a human beta-globin gene in murine bone marrow transplant recipients reconstituted with retrovirus-transduced stem cells. Nature. 1988;331(6151):35–41.",
      "volume": "331",
      "year": "1988"
    },
    {
      "DOI": "10.1016/j.bcmd.2006.05.001",
      "author": "T Nishino",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "issue": "1",
      "journal-title": "Blood Cells Mol Dis.",
      "key": "329_CR126",
      "unstructured": "Nishino T, Tubb J, Emery DW. Partial correction of murine beta-thalassemia with a gammaretrovirus vector for human gamma-globin. Blood Cells Mol Dis. 2006;37(1):1–7.",
      "volume": "37",
      "year": "2006"
    },
    {
      "DOI": "10.1517/14712598.6.5.509",
      "author": "RW Herzog",
      "doi-asserted-by": "publisher",
      "first-page": "509",
      "issue": "5",
      "journal-title": "Expert Opin Biol Ther.",
      "key": "329_CR127",
      "unstructured": "Herzog RW, Cao O, Hagstrom JN, Wang L. Gene therapy for treatment of inherited haematological disorders. Expert Opin Biol Ther. 2006;6(5):509–22.",
      "volume": "6",
      "year": "2006"
    },
    {
      "DOI": "10.1097/HS9.0000000000000479",
      "author": "JB Kunz",
      "doi-asserted-by": "publisher",
      "first-page": "e479",
      "issue": "5",
      "journal-title": "Hemasphere.",
      "key": "329_CR128",
      "unstructured": "Kunz JB, Kulozik AE. Gene Therapy of the Hemoglobinopathies. Hemasphere. 2020;4(5):e479.",
      "volume": "4",
      "year": "2020"
    },
    {
      "DOI": "10.1186/s12967-016-1047-x",
      "author": "JE Vargas",
      "doi-asserted-by": "publisher",
      "first-page": "288",
      "issue": "1",
      "journal-title": "J Transl Med.",
      "key": "329_CR129",
      "unstructured": "Vargas JE, Chicaybam L, Stein RT, Tanuri A, Delgado-Cañedo A, Bonamino MH. Retroviral vectors and transposons for stable gene therapy: advances, current challenges and perspectives. J Transl Med. 2016;14(1):288.",
      "volume": "14",
      "year": "2016"
    },
    {
      "DOI": "10.1016/j.hoc.2017.06.010",
      "author": "G Ferrari",
      "doi-asserted-by": "publisher",
      "first-page": "835",
      "issue": "5",
      "journal-title": "Hematol Oncol Clin North Am.",
      "key": "329_CR130",
      "unstructured": "Ferrari G, Cavazzana M, Mavilio F. Gene therapy approaches to hemoglobinopathies. Hematol Oncol Clin North Am. 2017;31(5):835–52.",
      "volume": "31",
      "year": "2017"
    },
    {
      "DOI": "10.1038/mt.2009.319",
      "author": "J Mátrai",
      "doi-asserted-by": "publisher",
      "first-page": "477",
      "issue": "3",
      "journal-title": "Mol Ther.",
      "key": "329_CR131",
      "unstructured": "Mátrai J, Chuah MK, VandenDriessche T. Recent advances in lentiviral vector development and applications. Mol Ther. 2010;18(3):477–90.",
      "volume": "18",
      "year": "2010"
    },
    {
      "DOI": "10.1038/35017565",
      "author": "C May",
      "doi-asserted-by": "publisher",
      "first-page": "82",
      "issue": "6791",
      "journal-title": "Nature.",
      "key": "329_CR132",
      "unstructured": "May C, Rivella S, Callegari J, Heller G, Gaensler KM, Luzzatto L, et al. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature. 2000;406(6791):82–6.",
      "volume": "406",
      "year": "2000"
    },
    {
      "DOI": "10.1073/pnas.0711666105",
      "author": "A Miccio",
      "doi-asserted-by": "publisher",
      "first-page": "10547",
      "issue": "30",
      "journal-title": "Proc Natl Acad Sci U S A.",
      "key": "329_CR133",
      "unstructured": "Miccio A, Cesari R, Lotti F, Rossi C, Sanvito F, Ponzoni M, et al. In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of beta-thalassemia. Proc Natl Acad Sci U S A. 2008;105(30):10547–52.",
      "volume": "105",
      "year": "2008"
    },
    {
      "DOI": "10.1038/s41591-018-0301-6",
      "author": "S Marktel",
      "doi-asserted-by": "publisher",
      "first-page": "234",
      "issue": "2",
      "journal-title": "Nat Med.",
      "key": "329_CR134",
      "unstructured": "Marktel S, Scaramuzza S, Cicalese MP, Giglio F, Galimberti S, Lidonnici MR, et al. Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ß-thalassemia. Nat Med. 2019;25(2):234–41.",
      "volume": "25",
      "year": "2019"
    },
    {
      "DOI": "10.1056/NEJMoa1705342",
      "author": "AA Thompson",
      "doi-asserted-by": "publisher",
      "first-page": "1479",
      "issue": "16",
      "journal-title": "N Engl J Med.",
      "key": "329_CR135",
      "unstructured": "Thompson AA, Walters MC, Kwiatkowski J, Rasko JEJ, Ribeil J-A, Hongeng S, et al. Gene therapy in patients with transfusion-dependent β-thalassemia. New England Journal of Medicine. N Engl J Med. 2018;378(16):1479–93.",
      "volume": "378",
      "year": "2018"
    },
    {
      "DOI": "10.1002/emmm.201000083",
      "author": "EA Roselli",
      "doi-asserted-by": "publisher",
      "first-page": "315",
      "issue": "8",
      "journal-title": "EMBO Mol Med.",
      "key": "329_CR136",
      "unstructured": "Roselli EA, Mezzadra R, Frittoli MC, Maruggi G, Biral E, Mavilio F, et al. Correction of β-thalassemia major by gene transfer in haematopoietic progenitors of pediatric patients. EMBO Mol Med. 2010;2(8):315–28.",
      "volume": "2",
      "year": "2010"
    },
    {
      "DOI": "10.1172/JCI67930",
      "author": "Z Romero",
      "doi-asserted-by": "publisher",
      "first-page": "3317",
      "journal-title": "J Clin Invest",
      "key": "329_CR137",
      "unstructured": "Romero Z, Urbinati F, Geiger S, Cooper AR, Wherley J, Kaufman ML, et al. β-globin gene transfer to human bone marrow for sickle cell disease. J Clin Invest. 2013;23:3317–30.",
      "volume": "23",
      "year": "2013"
    },
    {
      "DOI": "10.1016/j.bcmd.2017.12.001",
      "author": "MR Lidonnici",
      "doi-asserted-by": "publisher",
      "first-page": "87",
      "journal-title": "Blood Cells Mol Dis.",
      "key": "329_CR138",
      "unstructured": "Lidonnici MR, Ferrari G. Gene therapy and gene editing strategies for hemoglobinopathies. Blood Cells Mol Dis. 2018;70:87–101.",
      "volume": "70",
      "year": "2018"
    },
    {
      "DOI": "10.1182/blood-2014-12-615948",
      "author": "MD Hoban",
      "doi-asserted-by": "publisher",
      "first-page": "2597",
      "issue": "17",
      "journal-title": "Blood.",
      "key": "329_CR139",
      "unstructured": "Hoban MD, Cost GJ, Mendel MC, Romero Z, Kaufman ML, Joglekar AV, et al. Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells. Blood. 2015;125(17):2597–604.",
      "volume": "125",
      "year": "2015"
    },
    {
      "DOI": "10.1089/hum.2019.220",
      "author": "P Tornabene",
      "doi-asserted-by": "publisher",
      "first-page": "47",
      "issue": "1-2",
      "journal-title": "Hum Gene Ther.",
      "key": "329_CR140",
      "unstructured": "Tornabene P, Trapani I. Can adeno-associated viral vectors deliver effectively large genes? Hum Gene Ther. 2020;31(1-2):47–56.",
      "volume": "31",
      "year": "2020"
    },
    {
      "DOI": "10.1038/mt.2012.186",
      "author": "RC Münch",
      "doi-asserted-by": "publisher",
      "first-page": "109",
      "issue": "1",
      "journal-title": "Mol Ther.",
      "key": "329_CR141",
      "unstructured": "Münch RC, Janicki H, Völker I, Rasbach A, Hallek M, Büning H, et al. Displaying high-affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transfer. Mol Ther. 2013;21(1):109–18.",
      "volume": "21",
      "year": "2013"
    },
    {
      "DOI": "10.1586/ehm.11.48",
      "author": "D Raj",
      "doi-asserted-by": "publisher",
      "first-page": "539",
      "issue": "5",
      "journal-title": "Expert Rev Hematol.",
      "key": "329_CR142",
      "unstructured": "Raj D, Davidoff AM, Nathwani AC. Self-complementary adeno-associated viral vectors for gene therapy of hemophilia B: progress and challenges. Expert Rev Hematol. 2011;4(5):539–49.",
      "volume": "4",
      "year": "2011"
    },
    {
      "DOI": "10.1038/s41573-019-0012-9",
      "author": "D Wang",
      "doi-asserted-by": "publisher",
      "first-page": "358",
      "issue": "5",
      "journal-title": "Nat Rev Drug Discov.",
      "key": "329_CR143",
      "unstructured": "Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18(5):358–78.",
      "volume": "18",
      "year": "2019"
    },
    {
      "DOI": "10.1006/mthe.2001.0346",
      "author": "M Tan",
      "doi-asserted-by": "publisher",
      "first-page": "940",
      "issue": "6",
      "journal-title": "Mol Ther.",
      "key": "329_CR144",
      "unstructured": "Tan M, Qing K, Zhou S, Yoder MC, Srivastava A. Adeno-associated virus 2-mediated transduction and erythroid lineage-restricted long-term expression of the human beta-globin gene in hematopoietic cells from homozygous beta-thalassemic mice. Mol Ther. 2001;3(6):940–6.",
      "volume": "3",
      "year": "2001"
    },
    {
      "DOI": "10.1007/s12185-011-0823-x",
      "author": "J Tian",
      "doi-asserted-by": "publisher",
      "first-page": "691",
      "issue": "6",
      "journal-title": "Int J Hematol.",
      "key": "329_CR145",
      "unstructured": "Tian J, Wang F, Xue JF, Zhao F, Song LJ, Tan MQ. Recombinant AAV2-mediated β-globin expression in human fetal hematopoietic cells from the aborted fetuses with β-thalassemia major. Int J Hematol. 2011;93(6):691–9.",
      "volume": "93",
      "year": "2011"
    },
    {
      "DOI": "10.1038/s41591-021-01284-y",
      "author": "MK Cromer",
      "doi-asserted-by": "publisher",
      "first-page": "677",
      "issue": "4",
      "journal-title": "Nat Med.",
      "key": "329_CR146",
      "unstructured": "Cromer MK, Camarena J, Martin RM, Lesch BJ, Vakulskas CA, Bode NM, et al. Gene replacement of α-globin with β-globin restores hemoglobin balance in β-thalassemia-derived hematopoietic stem and progenitor cells. Nat Med. 2021;27(4):677–87.",
      "volume": "27",
      "year": "2021"
    },
    {
      "DOI": "10.1016/j.omtn.2020.03.009",
      "author": "H Yang",
      "doi-asserted-by": "publisher",
      "first-page": "451",
      "journal-title": "Mol Ther Nucleic Acids.",
      "key": "329_CR147",
      "unstructured": "Yang H, Qing K, Keeler GD, Yin L, Mietzsch M, Ling C, et al. Enhanced transduction of human hematopoietic stem cells by AAV6 Vectors: implications in gene therapy and genome editing. Mol Ther Nucleic Acids. 2020;20:451–8.",
      "volume": "20",
      "year": "2020"
    },
    {
      "DOI": "10.1016/j.omtn.2020.03.009",
      "author": "TI Cornu",
      "doi-asserted-by": "crossref",
      "first-page": "451",
      "journal-title": "Mol Ther Nucleic Acids.",
      "key": "329_CR148",
      "unstructured": "Cornu TI, Mussolino C, Cathomen T. Refining strategies to translate genome editing to the clinic. Mol Ther Nucleic Acids. 2020;20:451–8.",
      "volume": "20",
      "year": "2020"
    },
    {
      "DOI": "10.1038/s41392-019-0089-y",
      "author": "H Li",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "issue": "1",
      "journal-title": "Signal Transduct Target Ther.",
      "key": "329_CR149",
      "unstructured": "Li H, Yang Y, Hong W, Huang M, Wu M, Zhao X. Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Signal Transduct Target Ther. 2020;5(1):1.",
      "volume": "5",
      "year": "2020"
    },
    {
      "DOI": "10.5772/52704",
      "doi-asserted-by": "crossref",
      "key": "329_CR150",
      "unstructured": "Rodriguez A, del A, Angeles M. Non-viral delivery systems in gene therapy. Gene Therapy - Tools and Potential Applications. InTechOpen; 2013;1–33. Available from: https://www.intechopen.com/books/gene-therapy-tools-and-potential-applications/non-viral-delivery-systems-in-gene-therapy."
    },
    {
      "DOI": "10.1080/10409238.2017.1304354",
      "author": "M Hudecek",
      "doi-asserted-by": "publisher",
      "first-page": "355",
      "issue": "4",
      "journal-title": "Crit Rev Biochem Mol Biol.",
      "key": "329_CR151",
      "unstructured": "Hudecek M, Izsvák Z, Johnen S, Renner M, Thumann G, Ivics Z. Going non-viral: the Sleeping Beauty transposon system breaks on through to the clinical side. Crit Rev Biochem Mol Biol. 2017;52(4):355–80.",
      "volume": "52",
      "year": "2017"
    },
    {
      "DOI": "10.1016/j.omtn.2017.06.007",
      "author": "S Li",
      "doi-asserted-by": "publisher",
      "first-page": "64",
      "journal-title": "Mol Ther Nucleic Acids.",
      "key": "329_CR152",
      "unstructured": "Li S, Zhang A, Xue H, Li D, Liu Y. One-step piggybac transposon-based CRISPR/Cas9 activation of multiple genes. Mol Ther Nucleic Acids. 2017;8:64–76.",
      "volume": "8",
      "year": "2017"
    },
    {
      "DOI": "10.1182/blood-2009-03-210005",
      "author": "X Xue",
      "doi-asserted-by": "publisher",
      "first-page": "1319",
      "issue": "7",
      "journal-title": "Blood.",
      "key": "329_CR153",
      "unstructured": "Xue X, Huang X, Nodland SE, Mátés L, Ma L, Izsvák Z, et al. Stable gene transfer and expression in cord blood-derived CD34+ hematopoietic stem and progenitor cells by a hyperactive Sleeping Beauty transposon system. Blood. 2009;114(7):1319–30.",
      "volume": "114",
      "year": "2009"
    },
    {
      "DOI": "10.1371/journal.pone.0080403",
      "author": "LM Sjeklocha",
      "doi-asserted-by": "publisher",
      "first-page": "e80403",
      "issue": "11",
      "journal-title": "Plos One.",
      "key": "329_CR154",
      "unstructured": "Sjeklocha LM, Wong PY, Belcher JD, Vercellotti GM, Steer CJ. β-Globin sleeping beauty transposon reduces red blood cell sickling in a patient-derived CD34(+)-based in vitro model. Plos One. 2013;8(11):e80403.",
      "volume": "8",
      "year": "2013"
    },
    {
      "DOI": "10.1042/BSR20160614",
      "author": "J Tipanee",
      "doi-asserted-by": "publisher",
      "first-page": "BSR20160614",
      "issue": "6",
      "journal-title": "Biosci Rep.",
      "key": "329_CR155",
      "unstructured": "Tipanee J, Chai YC, VandenDriessche T, Chuah MK. Preclinical and clinical advances in transposon-based gene therapy. Biosci Rep. 2017;37(6):BSR20160614.",
      "volume": "37",
      "year": "2017"
    },
    {
      "author": "S Zhao",
      "first-page": "120",
      "issue": "1",
      "journal-title": "Transl Lung Cancer Res.",
      "key": "329_CR156",
      "unstructured": "Zhao S, Jiang E, Chen S, Gu Y, Shangguan AJ, Lv T, et al. PiggyBac transposon vectors: the tools of the human gene encoding. Transl Lung Cancer Res. 2016;5(1):120–5.",
      "volume": "5",
      "year": "2016"
    },
    {
      "DOI": "10.1101/gr.173427.114",
      "author": "F Xie",
      "doi-asserted-by": "publisher",
      "first-page": "1526",
      "issue": "9",
      "journal-title": "Genome Res.",
      "key": "329_CR157",
      "unstructured": "Xie F, Ye L, Chang JC, Beyer AI, Wang J, Muench MO, et al. Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac. Genome Res. 2014;24(9):1526–33.",
      "volume": "24",
      "year": "2014"
    },
    {
      "DOI": "10.1038/mt.2016.38",
      "author": "EP Papapetrou",
      "doi-asserted-by": "publisher",
      "first-page": "678",
      "issue": "4",
      "journal-title": "Mol Ther.",
      "key": "329_CR158",
      "unstructured": "Papapetrou EP, Schambach A. Gene insertion into genomic safe harbors for human gene therapy. Mol Ther. 2016;24(4):678–84.",
      "volume": "24",
      "year": "2016"
    },
    {
      "DOI": "10.1007/978-1-4939-7299-9_6",
      "author": "AC Dong",
      "doi-asserted-by": "publisher",
      "first-page": "155",
      "journal-title": "Adv Exp Med Biol.",
      "key": "329_CR159",
      "unstructured": "Dong AC, Rivella S. Gene Addition strategies for β-thalassemia and sickle cell anemia. Adv Exp Med Biol. 2017;1013:155–76.",
      "volume": "1013",
      "year": "2017"
    },
    {
      "DOI": "10.2174/1566523214666141127095336",
      "author": "O Negre",
      "doi-asserted-by": "publisher",
      "first-page": "64",
      "issue": "1",
      "journal-title": "Curr Gene Ther.",
      "key": "329_CR160",
      "unstructured": "Negre O, Bartholomae C, Beuzard Y, Cavazzana M, Christiansen L, Courne C, et al. Preclinical evaluation of efficacy and safety of an improved lentiviral vector for the treatment of \u0026#946;-thalassemia and sickle cell disease. Curr Gene Ther. 2015;15(1):64–81.",
      "volume": "15",
      "year": "2015"
    },
    {
      "DOI": "10.1016/j.exphem.2018.05.004",
      "author": "K Sii-Felice",
      "doi-asserted-by": "publisher",
      "first-page": "12",
      "journal-title": "Exp Hematol.",
      "key": "329_CR161",
      "unstructured": "Sii-Felice K, Giorgi M, Leboulch P, Payen E. Hemoglobin disorders: lentiviral gene therapy in the starting blocks to enter clinical practice. Exp Hematol. 2018;64:12–32.",
      "volume": "64",
      "year": "2018"
    },
    {
      "DOI": "10.1056/NEJMoa1609677",
      "author": "J-A Ribeil",
      "doi-asserted-by": "publisher",
      "first-page": "848",
      "issue": "9",
      "journal-title": "N Engl J Med.",
      "key": "329_CR162",
      "unstructured": "Ribeil J-A, Hacein-Bey-Abina S, Payen E, Magnani A, Semeraro M, Magrin E, et al. Gene therapy in a patient with sickle cell disease. N Engl J Med. 2017;376(9):848–55.",
      "volume": "376",
      "year": "2017"
    },
    {
      "DOI": "10.1002/jgm.3015",
      "author": "SL Ginn",
      "doi-asserted-by": "publisher",
      "first-page": "e3015",
      "issue": "5",
      "journal-title": "J Gene Med.",
      "key": "329_CR163",
      "unstructured": "Ginn SL, Amaya AK, Alexander IE, Edelstein M, Abedi MR. Gene therapy clinical trials worldwide to 2017: an update. J Gene Med. 2018;20(5):e3015.",
      "volume": "20",
      "year": "2018"
    },
    {
      "DOI": "10.1089/hum.2018.122",
      "author": "M Cavazzana",
      "doi-asserted-by": "publisher",
      "first-page": "1106",
      "issue": "10",
      "journal-title": "Hum Gene Ther.",
      "key": "329_CR164",
      "unstructured": "Cavazzana M, Mavilio F. Gene therapy for hemoglobinopathies. Hum Gene Ther. 2018;29(10):1106–13.",
      "volume": "29",
      "year": "2018"
    },
    {
      "DOI": "10.3324/haematol.2017.184788",
      "author": "C Lagresle-Peyrou",
      "doi-asserted-by": "publisher",
      "first-page": "778",
      "issue": "5",
      "journal-title": "Haematologica.",
      "key": "329_CR165",
      "unstructured": "Lagresle-Peyrou C, Lefrère F, Magrin E, Ribeil JA, Romano O, Weber L, et al. Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion. Haematologica. 2018;103(5):778–86.",
      "volume": "103",
      "year": "2018"
    },
    {
      "DOI": "10.1089/hum.2010.045",
      "author": "MC Frittoli",
      "doi-asserted-by": "publisher",
      "first-page": "507",
      "issue": "4",
      "journal-title": "Hum Gene Ther.",
      "key": "329_CR166",
      "unstructured": "Frittoli MC, Biral E, Cappelli B, Zambelli M, Roncarolo MG, Ferrari G, et al. Bone marrow as a source of hematopoietic stem cells for human gene therapy of β-thalassemia. Hum Gene Ther. 2011;22(4):507–13.",
      "volume": "22",
      "year": "2011"
    },
    {
      "DOI": "10.3324/haematol.2015.141200",
      "author": "A Srivastava",
      "doi-asserted-by": "publisher",
      "first-page": "214",
      "issue": "2",
      "journal-title": "Haematologica.",
      "key": "329_CR167",
      "unstructured": "Srivastava A, Shaji RV. Cure for thalassemia major—from allogeneic hematopoietic stem cell transplantation to gene therapy. Haematologica. 2017;102(2):214–23.",
      "volume": "102",
      "year": "2017"
    },
    {
      "DOI": "10.1042/BSR20200127",
      "author": "MP Hirakawa",
      "doi-asserted-by": "publisher",
      "first-page": "BSR20200127",
      "issue": "4",
      "journal-title": "Biosci Rep.",
      "key": "329_CR168",
      "unstructured": "Hirakawa MP, Krishnakumar R, Timlin JA, Carney JP, Butler KS. Gene editing and CRISPR in the clinic: current and future perspectives. Biosci Rep. 2020;40(4):BSR20200127.",
      "volume": "40",
      "year": "2020"
    },
    {
      "DOI": "10.1126/science.aat5011",
      "author": "GJ Knott",
      "doi-asserted-by": "publisher",
      "first-page": "866",
      "issue": "6405",
      "journal-title": "Science.",
      "key": "329_CR169",
      "unstructured": "Knott GJ, Doudna JA. CRISPR-Cas guides the future of genetic engineering. Science. 2018;361(6405):866–9.",
      "volume": "361",
      "year": "2018"
    },
    {
      "DOI": "10.1093/hmg/ddaa088",
      "author": "S Demirci",
      "doi-asserted-by": "publisher",
      "first-page": "R100",
      "issue": "R1",
      "journal-title": "Hum Mol Genet.",
      "key": "329_CR170",
      "unstructured": "Demirci S, Leonard A, Tisdale JF. Genome editing strategies for fetal hemoglobin induction in beta-hemoglobinopathies. Hum Mol Genet. 2020;29(R1):R100–6.",
      "volume": "29",
      "year": "2020"
    },
    {
      "DOI": "10.1126/scitranslmed.aaf9336",
      "author": "MA DeWitt",
      "doi-asserted-by": "publisher",
      "first-page": "360ra134",
      "issue": "360",
      "journal-title": "Sci Transl Med",
      "key": "329_CR171",
      "unstructured": "DeWitt MA, Magis W, Bray NL, Wang T, Berman JR, Urbinati F, et al. Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells. Sci Transl Med. 2016;8(360):360ra134.",
      "volume": "8",
      "year": "2016"
    },
    {
      "DOI": "10.1182/blood-2017-02-767400",
      "author": "B Wienert",
      "doi-asserted-by": "publisher",
      "first-page": "803",
      "issue": "6",
      "journal-title": "Blood.",
      "key": "329_CR172",
      "unstructured": "Wienert B, Martyn GE, Kurita R, Nakamura Y, Quinlan KGR, Crossley M. KLF1 drives the expression of fetal hemoglobin in British HPFH. Blood. 2017;130(6):803–7.",
      "volume": "130",
      "year": "2017"
    },
    {
      "DOI": "10.1038/mt.2015.113",
      "author": "S Guda",
      "doi-asserted-by": "publisher",
      "first-page": "1465",
      "issue": "9",
      "journal-title": "Mol Ther.",
      "key": "329_CR173",
      "unstructured": "Guda S, Brendel C, Renella R, Du P, Bauer DE, Canver MC, et al. MiRNA-embedded shRNAs for lineage-specific BCL11A knockdown and hemoglobin F induction. Mol Ther. 2015;23(9):1465–74.",
      "volume": "23",
      "year": "2015"
    },
    {
      "DOI": "10.1126/science.1242088",
      "author": "DE Bauer",
      "doi-asserted-by": "publisher",
      "first-page": "253",
      "issue": "6155",
      "journal-title": "Science.",
      "key": "329_CR174",
      "unstructured": "Bauer DE, Kamran SC, Lessard S, Xu J, Fujiwara Y, Lin C, et al. An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level. Science. 2013;342(6155):253–7.",
      "volume": "342",
      "year": "2013"
    },
    {
      "DOI": "10.1038/nm.4170",
      "author": "EA Traxler",
      "doi-asserted-by": "publisher",
      "first-page": "987",
      "issue": "9",
      "journal-title": "Nat Med.",
      "key": "329_CR175",
      "unstructured": "Traxler EA, Yao Y, Wang YD, Woodard KJ, Kurita R, Nakamura Y, et al. A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition. Nat Med. 2016;22(9):987–90.",
      "volume": "22",
      "year": "2016"
    },
    {
      "DOI": "10.1182/blood-2017-10-811505",
      "author": "C Antoniani",
      "doi-asserted-by": "publisher",
      "first-page": "1960",
      "issue": "17",
      "journal-title": "Blood.",
      "key": "329_CR176",
      "unstructured": "Antoniani C, Meneghini V, Lattanzi A, Felix T, Romano O, Magrin E, et al. Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human b-globin locus. Blood. 2018;131(17):1960–73.",
      "volume": "131",
      "year": "2018"
    },
    {
      "DOI": "10.1073/pnas.1612075113",
      "author": "L Ye",
      "doi-asserted-by": "publisher",
      "first-page": "10661",
      "issue": "38",
      "journal-title": "Proc Natl Acad Sci U S A.",
      "key": "329_CR177",
      "unstructured": "Ye L, Wang J, Tan Y, Beyer AI, Xie F, Muench MO, et al. Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: an approach for treating sickle cell disease and β-thalassemia. Proc Natl Acad Sci U S A. 2016;113(38):10661–5.",
      "volume": "113",
      "year": "2016"
    },
    {
      "DOI": "10.1038/ncomms8085",
      "author": "B Wienert",
      "doi-asserted-by": "publisher",
      "first-page": "7085",
      "journal-title": "Nat Commun.",
      "key": "329_CR178",
      "unstructured": "Wienert B, Funnell APW, Norton LJ, Pearson RCM, Wilkinson-White LE, Lester K, et al. Editing the genome to introduce a beneficial naturally occurring mutation associated with increased fetal globin. Nat Commun. 2015;6:7085.",
      "volume": "6",
      "year": "2015"
    },
    {
      "DOI": "10.1038/nature20134",
      "author": "DP Dever",
      "doi-asserted-by": "publisher",
      "first-page": "384",
      "issue": "7629",
      "journal-title": "Nature.",
      "key": "329_CR179",
      "unstructured": "Dever DP, Bak RO, Reinisch A, Camarena J, Washington G, Nicolas CE, et al. CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells. Nature. 2016;539(7629):384–9.",
      "volume": "539",
      "year": "2016"
    },
    {
      "DOI": "10.1002/stem.1969",
      "author": "X Huang",
      "doi-asserted-by": "publisher",
      "first-page": "1470",
      "issue": "5",
      "journal-title": "Stem Cells.",
      "key": "329_CR180",
      "unstructured": "Huang X, Wang Y, Yan W, Smith C, Ye Z, Wang J, et al. Production of gene-corrected adult beta globin protein in human erythrocytes differentiated from patient ipscs after genome editing of the sickle point mutation. Stem Cells. 2015;33(5):1470–9.",
      "volume": "33",
      "year": "2015"
    },
    {
      "DOI": "10.1002/bit.25018",
      "author": "N Sun",
      "doi-asserted-by": "publisher",
      "first-page": "1048",
      "issue": "5",
      "journal-title": "Biotechnol Bioeng.",
      "key": "329_CR181",
      "unstructured": "Sun N, Zhao H. Seamless correction of the sickle cell disease mutation of the HBB gene in human induced pluripotent stem cells using TALENs. Biotechnol Bioeng. 2014;111(5):1048–53.",
      "volume": "111",
      "year": "2014"
    },
    {
      "DOI": "10.1038/nprot.2017.143",
      "author": "RO Bak",
      "doi-asserted-by": "publisher",
      "first-page": "358",
      "issue": "2",
      "journal-title": "Nat Protocols.",
      "key": "329_CR182",
      "unstructured": "Bak RO, Dever DP, Porteus MH. CRISPR/Cas9 genome editing in human hematopoietic stem cells. Nat Protocols. 2018;13(2):358–76.",
      "volume": "13",
      "year": "2018"
    },
    {
      "key": "329_CR183",
      "unstructured": "CRISPR Therapeutics, AG. 2021. http://www.crisprtx.com. Accessed 10/09/2020."
    },
    {
      "DOI": "10.1016/j.ejphar.2019.04.042",
      "author": "MA Khosravi",
      "doi-asserted-by": "publisher",
      "first-page": "398",
      "journal-title": "Eur J Pharmacol",
      "key": "329_CR184",
      "unstructured": "Khosravi MA, Abbasalipour M, Concordet JP, Vom BJ, Zeinali S, Arashkia A, et al. Targeted deletion of BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: a promising approach for gene therapy of beta thalassemia disease. Eur J Pharmacol. 2019;854:398–405.",
      "volume": "854",
      "year": "2019"
    },
    {
      "DOI": "10.1016/j.omtm.2016.12.009",
      "author": "KH Chang",
      "doi-asserted-by": "publisher",
      "first-page": "137",
      "journal-title": "Mol Ther Methods Clin Dev.",
      "key": "329_CR185",
      "unstructured": "Chang KH, Smith SE, Sullivan T, Chen K, Zhou Q, West JA, et al. Long-term engraftment and fetal globin induction upon BCL11A gene editing in bone-marrow-derived CD34+ hematopoietic stem and progenitor cells. Mol Ther Methods Clin Dev. 2017;4:137–48.",
      "volume": "4",
      "year": "2017"
    },
    {
      "DOI": "10.1038/nrd.2016.238",
      "author": "C Fellmann",
      "doi-asserted-by": "publisher",
      "first-page": "89",
      "issue": "2",
      "journal-title": "Nat Rev Drug Discov.",
      "key": "329_CR186",
      "unstructured": "Fellmann C, Gowen BG, Lin PC, Doudna JA, Corn JE. Cornerstones of CRISPR-Cas in drug discovery and therapy. Nat Rev Drug Discov. 2017;16(2):89–100.",
      "volume": "16",
      "year": "2017"
    },
    {
      "DOI": "10.1016/j.cell.2015.09.038",
      "author": "B Zetsche",
      "doi-asserted-by": "publisher",
      "first-page": "759",
      "issue": "3",
      "journal-title": "Cell.",
      "key": "329_CR187",
      "unstructured": "Zetsche B, Gootenberg JS, Abudayyeh OO, Slaymaker IM, Makarova KS, Essletzbichler P, et al. Cpf1 Is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell. 2015;163(3):759–71.",
      "volume": "163",
      "year": "2015"
    },
    {
      "DOI": "10.1038/nature16526",
      "author": "BP Kleinstiver",
      "doi-asserted-by": "publisher",
      "first-page": "490",
      "issue": "7587",
      "journal-title": "Nature.",
      "key": "329_CR188",
      "unstructured": "Kleinstiver BP, Pattanayak V, Prew MS, Tsai SQ, Nguyen NT, Zheng Z, et al. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature. 2016;529(7587):490–5.",
      "volume": "529",
      "year": "2016"
    },
    {
      "DOI": "10.1038/s41598-020-66309-x",
      "author": "A Lamsfus-Calle",
      "doi-asserted-by": "publisher",
      "first-page": "10133",
      "issue": "1",
      "journal-title": "Sci Rep.",
      "key": "329_CR189",
      "unstructured": "Lamsfus-Calle A, Daniel-Moreno A, Antony JS, Epting T, Heumos L, Baskaran P, et al. Comparative targeting analysis of KLF1, BCL11A, and HBG1/2 in CD34+ HSPCs by CRISPR/Cas9 for the induction of fetal hemoglobin. Sci Rep. 2020;10(1):10133.",
      "volume": "10",
      "year": "2020"
    },
    {
      "DOI": "10.1182/blood-2015-09-618553",
      "author": "MJ Telen",
      "doi-asserted-by": "publisher",
      "first-page": "810",
      "issue": "7",
      "journal-title": "Blood.",
      "key": "329_CR190",
      "unstructured": "Telen MJ. Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease. Blood. 2016;127(7):810–9.",
      "volume": "127",
      "year": "2016"
    },
    {
      "DOI": "10.1186/s12920-019-0527-2",
      "author": "M Gulilat",
      "doi-asserted-by": "publisher",
      "first-page": "81",
      "issue": "1",
      "journal-title": "BMC Med Genomics.",
      "key": "329_CR191",
      "unstructured": "Gulilat M, Lamb T, Teft WA, Wang J, Dron JS, Robinson JF, et al. Targeted next generation sequencing as a tool for precision medicine. BMC Med Genomics. 2019;12(1):81.",
      "volume": "12",
      "year": "2019"
    },
    {
      "DOI": "10.1101/cshperspect.a033027",
      "author": "UI Schwarz",
      "doi-asserted-by": "publisher",
      "first-page": "a033027",
      "issue": "2",
      "journal-title": "Cold Spring Harb Perspect Med.",
      "key": "329_CR192",
      "unstructured": "Schwarz UI, Gulilat M, Kim RB. The role of next-generation sequencing in pharmacogenetics and pharmacogenomics. Cold Spring Harb Perspect Med. 2019;9(2):a033027.",
      "volume": "9",
      "year": "2019"
    },
    {
      "DOI": "10.1186/s40824-019-0156-z",
      "author": "YK Sung",
      "doi-asserted-by": "publisher",
      "first-page": "8",
      "journal-title": "Biomater Res.",
      "key": "329_CR193",
      "unstructured": "Sung YK, Kim SW. Recent advances in the development of gene delivery systems. Biomater Res. 2019;23:8.",
      "volume": "23",
      "year": "2019"
    },
    {
      "DOI": "10.15252/emmm.201809958",
      "author": "L Naldini",
      "doi-asserted-by": "publisher",
      "first-page": "e9958",
      "issue": "3",
      "journal-title": "EMBO Mol Med.",
      "key": "329_CR194",
      "unstructured": "Naldini L. Genetic engineering of hematopoiesis: current stage of clinical translation and future perspectives. EMBO Mol Med. 2019;11(3):e9958.",
      "volume": "11",
      "year": "2019"
    },
    {
      "DOI": "10.1016/j.ebiom.2017.08.015",
      "author": "X Shang",
      "doi-asserted-by": "publisher",
      "first-page": "150",
      "journal-title": "EBioMedicine",
      "key": "329_CR195",
      "unstructured": "Shang X, Peng Z, Ye Y, Asan ZX, Chen Y, et al. Rapid targeted next-generation sequencing platform for molecular screening and clinical genotyping in subjects with hemoglobinopathies. EBioMedicine. 2017;23:150–9.",
      "volume": "23",
      "year": "2017"
    },
    {
      "DOI": "10.1038/gim.2014.122",
      "author": "Y Xue",
      "doi-asserted-by": "publisher",
      "first-page": "444",
      "issue": "6",
      "journal-title": "Genet Med.",
      "key": "329_CR196",
      "unstructured": "Xue Y, Ankala A, Wilcox WR, Hegde MR. Solving the molecular diagnostic testing conundrum for Mendelian disorders in the era of next-generation sequencing: Single-gene, gene panel, or exome/genome sequencing. Genet Med. 2015;17(6):444–51.",
      "volume": "17",
      "year": "2015"
    },
    {
      "DOI": "10.1038/d41586-019-03698-8",
      "author": "H Ledford",
      "doi-asserted-by": "publisher",
      "first-page": "22",
      "issue": "7785",
      "journal-title": "Nature.",
      "key": "329_CR197",
      "unstructured": "Ledford H. Gene therapy is facing its biggest challenge yet. Nature. 2019;576(7785):22–5.",
      "volume": "576",
      "year": "2019"
    },
    {
      "DOI": "10.1089/humc.2018.201",
      "author": "V Shukla",
      "doi-asserted-by": "publisher",
      "first-page": "102",
      "issue": "3",
      "journal-title": "Hum Gene Ther Clin Dev.",
      "key": "329_CR198",
      "unstructured": "Shukla V, Seoane-Vazquez E, Fawaz S, Brown L, Rodriguez-Monguio R. The landscape of cellular and gene therapy products: authorization, discontinuations, and cost. Hum Gene Ther Clin Dev. 2019;30(3):102–13.",
      "volume": "30",
      "year": "2019"
    },
    {
      "DOI": "10.1093/jalm/jfaa113",
      "author": "S Siamoglou",
      "doi-asserted-by": "publisher",
      "first-page": "1005",
      "issue": "5",
      "journal-title": "J Appl Lab Med.",
      "key": "329_CR199",
      "unstructured": "Siamoglou S, Karamperis K, Mitropoulou C, Patrinos GP. Costing methods as a means to measure the costs of pharmacogenomics testing. J Appl Lab Med. 2020;5(5):1005–16.",
      "volume": "5",
      "year": "2020"
    },
    {
      "DOI": "10.1038/tpj.2017.21",
      "author": "M Verbelen",
      "doi-asserted-by": "publisher",
      "first-page": "395",
      "issue": "5",
      "journal-title": "Pharmacogenomics J.",
      "key": "329_CR200",
      "unstructured": "Verbelen M, Weale ME, Lewis CM. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet? Pharmacogenomics J. 2017;17(5):395–402.",
      "volume": "17",
      "year": "2017"
    },
    {
      "DOI": "10.3389/fphar.2019.00830",
      "author": "S Simeonidis",
      "doi-asserted-by": "publisher",
      "first-page": "830",
      "journal-title": "Front Pharmacol.",
      "key": "329_CR201",
      "unstructured": "Simeonidis S, Koutsilieri S, Vozikis A, Cooper DN, Mitropoulou C, Patrinos GP. Application of economic evaluation to assess feasibility for reimbursement of genomic testing as part of personalized medicine interventions. Front Pharmacol. 2019;10:830.",
      "volume": "10",
      "year": "2019"
    },
    {
      "DOI": "10.1089/hum.2018.178",
      "author": "S Coquerelle",
      "doi-asserted-by": "publisher",
      "first-page": "753",
      "issue": "6",
      "journal-title": "Hum Gene Ther.",
      "key": "329_CR202",
      "unstructured": "Coquerelle S, Ghardallou M, Rais S, Taupin P, Touzot F, Boquet L, et al. Innovative curative treatment of beta thalassemia: cost-efficacy analysis of gene therapy versus allogenic hematopoietic stem-cell transplantation. Hum Gene Ther. 2019;30(6):753–61.",
      "volume": "30",
      "year": "2019"
    }
  ],
  "reference-count": 202,
  "references-count": 202,
  "resource": {
    "primary": {
      "URL": "https://humgenomics.biomedcentral.com/articles/10.1186/s40246-021-00329-0"
    }
  },
  "score": 0,
  "short-container-title": [
    "Hum Genomics"
  ],
  "source": "Crossref",
  "title": [
    "Genome-based therapeutic interventions for β-type hemoglobinopathies"
  ],
  "type": "journal-article",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "volume": "15"
}